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1 Introduction 
 
1.1 Early life stress model 
1.1.1 Early life stress as a risk factor 
Early life events can have a life-long impact on physical and mental health. There is 
increasing evidence that childhood trauma and neglect can profoundly influence 
behavior and increase risk for depression, anxiety disorders and substance abuse (de 
Wilde et al., 1992; Dube et al., 2001) (Kendler et al., 1995; Johnson et al., 2002). The 
quality of mother-infant interactions is of crucial importance during early 
development. Abundant evidence shows that postnatal disruption of the normal 
mother-infant interaction can lead to critical changes in the developing 
neuroendocrine response to stress in rodents. In fact, numerous studies have shown 
that early life stress can alter behavioral and neuro ndocrine responsiveness and brain 
morphology. Subsequent dysregulation of the hypothalamic-pituitary-adrenal (HPA) 
axis can increase the vulnerability to psychiatric d seases (Arborelius et al., 1999; 
Jaffee et al., 2002; Newport et al., 2002; Iversen et al., 2007; Rikhye et al., 2008).  
Such findings have raised the question of whether similar processes take place in the 
human infant and, if so, through which mechanism early life adversity programs the 
infant HPA axis. To address these questions, I will first briefly describe the anatomy 
and regulation of the HPA axis and focus on critical time windows for programming 
by adverse events. A rodent model of early life strss will be introduced to show how 
early experiences modulate behavioral, cognitive and physiological development. 
1.1.2 Hypothalamic-pituitary-adrenal (HPA) axis 
Hyperactivity of the HPA axis is one of the key find gs described in major 
depression (Holsboer, 2000). Secretion of hypothalamic corticotrophin-releasing 
hormone (CRH) from nerve terminals in the median emin nce into the hypophysial 
portal circulation stimulates the synthesis of the precursor protein 
proopiomelanocortin (POMC), its cleavage and release  adrenocorticotrophic 
hormone (ACTH) from the anterior pituitary. Although CRH is the primary ACTH 
secretagogue, other neuroactive peptides, in particular arginine vasopressin (AVP), 
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are coexpressed in parvocellular neurons of the hypot alamic paraventricular nucleus 
(PVN); these act synergistically with CRH to stimulate ACTH release under sustained 
stress (Plotsky et al., 1991; Sawchenko et al., 1993). When released into the systemic 
circulation, ACTH stimulates adrenocortical synthesis and release of cortisol (human) 
or corticosterone (rodents) from the adrenal gland, which in turn, inhibits CRH and 
AVP production via a negative feedback loop (Figure 1). 
 
 
 
 
 
 
Figure1. The hypothalamic-pituitary-adrenal (HPA) axis. The neuropeptides corticotrophin-
releasing hormone (CRH) and arginine vasopressin (AVP) are expressed in the parvocelluar 
neurons of the hypothalamic nucleus paraventricularis. The co-release of CRH and AVP into the 
portal blood vessels leads to potent stimulation of anterior pituitary ACTH secretion and POMC 
transcription. ACTH is derived from the POMC precursor mRNA and in turn stimulates secretion 
and synthesis of stress hormones (corticosteroids; CORT) by the adrenal glands. The activational 
effects of the HPA axis are counteracted by the inhib tory effects of CORT on the hypothalamus 
and pituitary and serve to attenuate and determinate the stress response. Adopted from 
(Murgatroyd et al., 2010) 
 
 
1.1.3 Stress hypo-responsive period (SHRP) 
Rodents undergo a period in early postnatal development during which they exhibit a 
reduced response to stress (stress hypo-responsive period, SHRP). This period has 
been suggested to last from  approximately postnatal day (PND) 4 to PND 14 
(Schapiro et al., 1962; Sapolsky and Meaney, 1986; Walker et al., 1986; Levine, 
1994, 2001) in rats and from PND 1-12 in mice (Cirulli et al., 1994; Schmidt et al., 
2002; Schmidt et al., 2003). This period is characterized by lower baseline plasma 
corticosterone concentrations than those measured at later stages of development and 
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in mature mice, and by blunted CRH and ACTH responses to acute stressors. During 
the SHRP, the adrenal gland is relatively insensitive to ACTH stimulation, resulting in 
only a minimal amount of corticosterone release upon stress (Stanton et al., 1988; 
Rosenfeld et al., 1991). The HPA axis is a dynamic system which undergoes postnatal 
maturation. During the first two weeks of life, the rodent brain passes through a 
number of critical developmental processes including dendritic outgrowth, 
synaptogenesis, and the formation of neural circuits. As a consequence, adverse 
events during the SHRP can lead to long term behavior l and physiological changes 
later in life. For example, during the SHRP, neonatal rat pups displayed increased cell 
death of neurons and glia in several cortical regions when subjected to a single (24 
hour) bout. However, the same paradigm is less harmful when applied outside the 
SHRP (Zhang et al., 2002). The quality of maternal behaviors, such as 
licking/grooming and feeding received during the early weaning period have 
significant impact on anxiety- and depression-like behaviour and HPA activity and 
these effects can persist into adulthood (Liu et al., 1997). Based on these observations, 
several animal models have been developed building up on the manipulation of the 
interaction between mother and pups during the critical period; one of these is 
maternal separation.  
1.1.4 Maternal separation (MS) of newborn mice 
Neonatal maternal separation (MS) has been used as a model of adverse early life 
events to induce long-term changes in behaviour and neuroendocrine regulation 
(Anisman et al., 1998; Slotten et al., 2006). This model is based on the observation 
that dams often leave their pups for foraging for 15-30 minutes, while a mother living 
in a harsh environment (e.g. drought) may have to forage for up to 2-3 hours, 
exposing the pups to increased separation stress. In the MS model, pups are separated 
for 3 hours daily from their mother during the first 10 days of life.  These 
manipulations are normally performed in the morning with the pups removed to an 
incubator or heating pad to maintain body temperature. From postnatal day 11, pups 
are reared by their mother, undisturbed in the home cage until PND 21 when they are 
weaned and housed in sex-matched groups (3-5 mice per cage). 
Maternal separation performed in this time window (PND 1-10) can confer 
detrimental effects to the neonatal pups when they reach adulthood. Until weaning, 
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pups are almost entirely dependent on their mother for the maintenance of body 
temperature, nutrition, and protection from predators, and in addition, their brains are 
undergoing significant development (the rodent brain at birth is thought to correspond 
to that of a human infant’s at gestational age 23-24 weeks). In this respect, early 
trauma can impose severe changes to the offspring. In general, many early-life stress 
paradigms induce persistent increases in anxiety- and depression-like behaviours, as 
well as hyperactivation of the HPA axis.  
As adults, animals that have experienced maternal separation stress show several 
behavioural alterations. They spend more time in the closed arm of the elevated plus 
maze when compared with control animals, suggesting a  anxiety-like phenotype 
(Romeo et al., 2003). Slotten and colleagues (Slotten et al., 2006) pointed out that 
adult rats previously exposed to 3 hours of daily separation (PND 3-15) preferentially 
stayed in the closed protected arm of the T-maze compared with the control rats. In 
addition, MS animals also exhibit depression-like behaviour. For example, rodents 
exposed to 3 hours of daily separation during the first two weeks of life spend more 
time floating in the force swim test when compared with control animals; this is 
thought to reflect depression-like behaviour. Maternal separation can also produce 
other depression-like syndromes, including increased consumption of ethanol 
(Pohorecky, 1981, 2006) and signs of anhedonia (the inability to perceive or respond 
appropriately to pleasurable stimuli) (Matthews andRobbins, 2003). 
Maternal separation can lead to long-lasting alterations of neuroendocrine 
regulation. When compared with control animals, adult MS offspring displays higher 
levels of basal corticosterone (CORT) and adrenocorticot opic hormone (ACTH), and 
increased level of hypothalamic CRH and AVP in the PVN. The adult MS animals 
exhibit resistance to glucocorticoid-mediated feedback, as evident from a failure of 
the dexamethasone suppression test (Murgatroyd et al., 2009). Furthermore, MS 
treated animals show decreased levels of gama amino butyric acid A (GABAA) 
receptor expression in the medial prefrontal cortex, noradrenergic (NA) cell body 
regions of the nucleus tractus solitarius and the locus coeruleus (Caldji et al., 2000). 
Moreover, reduced levels of brain-derived neurotropic factor (BDNF) and 
synaptophysin mRNA densities were detected (Lippmann et al., 2007; Aisa et al., 
2009). Maternal separation can also inhibit neurogenesis in the hippocampus，which 
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consequently impairs memory formation. Aisa and colleagues (Aisa et al., 2009) 
found that MS treated animals showed spatial learning deficits when tested in the 
Morris Water Maze compared with non-handled controls. 
1.1.5 Early life environment and the epigenome 
A critical question concerns the mechanisms coupling early social environment to 
long-term alterations of behaviour and stress respon es later in life. Recent findings 
from rodent models implied that epigenetic mechanisms, especially DNA 
methylation, are mediating the gene X environment dialogue by laying down stable 
marks in the genome, thus affecting the phenotype later in life. In the rat, different 
levels of maternal care early in life can lead to DNA methylation changes that persist, 
along with altered behavioral and neuroendocrine phnotypes in adulthood. Meaney 
and coworkers (Weaver et al., 2004) showed that pups reared under high maternal 
care, including licking/grooming and arch-back nursing (LG-ABN), have increased 
glucocorticoid receptor (GR) expression in the hippocampus when compared with 
pups reared by low LG-ABN dams. This higher glucocorti id receptor (NR3C1, GR) 
mRNA expression is associated with lower DNA methylation in the promoter region 
of the GR, thereby facilitating the binding of the transcription factor nerve growth 
factor-induced protein A (NGFI-A). The authors further performed a series of 
experiments to show that the impact of early experience can be reversed by later 
interventions in adulthood, e.g. environmental enrichment, cross-fostering or 
treatment with histone deacetylase (HDAC) inhibitors.  This example demonstrated 
that changes in the epigenome established by the environment during early 
development can be reversed in adulthood, indicating the plasticity of DNA 
methylation processes in the adult brain. 
In humans, adverse events such as childhood abuse can also lead to epigenetic 
programming in the adult brain. McGowan and coworkers (McGowan et al., 2009) 
found that DNA methylation at a neuron-specific GR promoter was significantly 
higher in the hippocampus of suicide victims who had suffered from childhood abuse 
than in controls or non-abused suicide victims. The increased DNA methylation in 
suicide victims who underwent childhood abuse is associated with decreased levels of 
GR mRNA as well as the GR 1F splice variant, suggesting a functional correlation 
between DNA methylation and GR mRNA expression. Thus, the findings in rodent 
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models implicating early environmental exposure in programming the epigenome also 
appears to apply to humans.  In sum, results both fr m animal models and humans 
indicate the plasticity of the epigenome when exposed to environmental stimuli, 
opening the possibility of developing approaches for early diagnosis, prevention, and 
treatment of disease. 
 
1.2 DNA methylation and MeCP2 
1.2.1 Epigenetics 
The term “epigenetics” was first introduced by the developmental biologist Conrad 
Waddington in 1940 to describe the gene-environment interactions that result in 
specific phenotypes (Waddington, 1942; Van Speybroeck, 2002). While Waddington 
originally used this concept in a developmental context, the term’s current use has 
extended to describe the study of heritable changes (both mitotic and meiotic) in gene 
expression that are not due to changes in DNA sequence (Russo, 1996). The concept 
of epigenetics was recently revised by the British scientist Adrian Bird who proposed  
that epigenetic events are the structural adaptation of chromosomal regions (genes) to 
register, signal or perpetuate altered activity state  (Bird, 2007). In this new definition 
of epigenetics, both chromatin marks and DNA modifications, regardless of their 
heritability, are considered as epigenetic events. DNA methylation and histone 
modifications are the two main mechanisms of epigenetic regulation. Whereas histone 
modifications are often transient events, DNA methylation is thought of as a stable 
modification of DNA. In our studies, we focused on DNA methylation. 
1.2.2 DNA methylation 
DNA methylation is a covalent chemical modification involving the addition of a 
methyl group to the fifth position of the pyrimidine ring in the nucleotide cytosine. 
This modification can be inherited through cell division. DNA methylation is 
normally removed during zygote formation and reestablished by de novo methylation. 
In mammals, DNA methylation mostly occurs in the context of CpG dinucleotides, 
which consist of a cytosine immediately followed by a guanine (Richards, 2006). In 
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addition, recent research revealed that DNA methylaion can also appear in a non-
CpG manner, although the function of this is still not very clear (Barres et al., 2009). 
It has been suggested that about 25% of all methylation in embryonic stem (ES) cells 
occurs in a non-CpG context. Non-CpG methylation disappears during differentiation, 
but is restored in induced pluripotent stem cells, suggesting that non-CpG methylation 
might play a role in the establishment and maintenance of pluripotency (Lister et al., 
2009). 
 About 70% of all CpG dinucleotides are methylated across the genome (Ehrlich 
et al., 1982), except for the high CpG density regions called CpG islands (Bird, 1986; 
Gardiner-Garden and Frommer, 1987). The common formal definition of a CpG 
island is a region spanning at least 200 bp in length and containing a GC percentage 
greater than 50% with an observed/expected CpG ratio of more than 60%. Another 
recent study revised the rules for CpG island prediction in order to exclude other GC-
rich genomic sequences such as Alu repeats. Accordingly, CpG islands are defined as 
DNA regions of >500 bp with a GC content >55% and observed CpG/expected CpG 
ratio of 0.65 (Takai and Jones, 2002). CpG islands are normally present within or 
close to the promoter region responsible for regulating the transcription rate of a gene. 
Typically, CpG islands are free of methylation. New studies by Weber and coworkers 
(Weber et al., 2007) have pointed out that DNA methylation at a given CpG island is 
dependent on the CpG density of the promoter. High CpG promoters are 
unmethylated and promoters with low CpG contents tend o be hypermethylated. 
DNA methylation has been shown to play important roles in mammalian 
development. For example, DNA methylation is essential for establishing tissue-
specific gene expression patterns. In addition, DNA methylation is also associated 
with a number of key processes such as X-chromosome inactivation, parental 
imprinting, suppression of repetitive elements and carcinogenesis (Bird, 2002).  
1.2.3 DNA methyltransferases 
In mammalian cells, DNA methylation occurs mainly at the 5 position of CpG 
dinucleotides and is catalyzed by DNA methyltransferas s (DNMTs). There are four 
known DNMTs which can be subcategorized into two grups by their functions: de 
novo and maintenance DNA methylation. 
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The addition of methyl groups to previously unmethylated DNA, the so called e 
novo methylation, is catalyzed by two enzymes: DNMT3a and DNMT3b. Compared 
with DNMT3a, DNMT3b shows relatively low expression in most tissues except for 
the testis, suggesting a crucial function for DNMT3b in spermatogenesis (Okano et 
al., 1998a; Robertson et al., 1999; Xie et al., 1999). DNMT3a and DNMT3b are 
essential for normal development (Okano et al., 1999). Dnmt3a homozygous 
knockout mice appear normal at birth but die after 4 weeks of age; while Dnmt3b 
homozygous knockout mice show various embryonic defects and die before E15.5. 
Combined knock-out of Dnmt3a and Dnmt3b produces more severe symptoms than 
those of Dnmt3a and Dnmt3b alone. This indicates that Dnmt3a and Dnmt3b have at 
least partially overlapping functions in the establishment of cellular DNA methylation 
patterns during development.   
Maintenance DNA methylation activity is essential for preserving DNA 
methylation patterns in each cellular DNA replication cycle. DNMT1 functions as a 
maintenance DNA methyltransferase, and specifically recognizes hemi-methylated 
CpGs following DNA replication of the daughter strand. DNMT1 is responsible for 
transmitting DNA methylation patterns to the daughter strand. Dnmt1 is essential for 
mammalian development, because null mutants show widespread demethylation in 
the embryo and die at E9.5 (Li et al., 1992). Dnmt1 mRNA expression is also 
observed in low-proliferation tissues such as the adult heart and brain. These 
unexpected results suggest a new role of Dnmt1 in addition to its known role to 
maintain DNA methylation levels during cell division. Recent finding suggests that 
DNMT1 can interact with methyl-CpG binding proteins a  well as with HDACs and 
histone methyltransferases to exert transcriptional repression (Tatematsu et al., 2000; 
Fuks et al., 2003a; Kimura and Shiota, 2003). 
In 1998, scientists seeking to identify a putative de novo DNA methyltransferase 
discovered the DNMT2 gene (Okano et al., 1998b). DNMT2 contains the well-
conserved catalytic domain. However, only traceable methyltransferase activity of the 
DNMT2 gene was found using in vitro systems (Hermann et al., 2003). Moreover, 
Dnmt2 knockout ES cells show normal de novo or maintenance methyltransferase 
function (Okano et al., 1998b). Consistent with this finding, Dnmt2 knockout mice 
fail to display an abnormal phenotype. Recent research showed that human DNMT2 
can work as a tRNA methyltransferase which specifically methylates cytosine 38 in 
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the anticodon loop (Goll et al., 2006). However, it is not known how many RNA 
species can be methylated by Dnmt2. Thus the functio s of DNMT2 still need to be 
determined in the future. 
DNMT3L is highly expressed in the testis and embryos, and is likely to play a 
role in the setting of imprints in oocytes (Bourc'his et al., 2001; Margot et al., 2003). 
Unlike the other DNMTs, no functionally relevant catalytic motif was mapped in the 
DNMT3L protein sequence and DNMT3L has not been associated with intrinsic 
enzymatic activity until now.   
1.2.4  Readers of DNA methylation 
The best documented function of DNA methylation is gene silencing. DNA 
methylation may affect gene expression in two ways. Firstly, if the DNA sequence is 
methylated, the methylation of DNA itself might impede the binding of a specific 
transcriptional factor to its recognition site and suppress gene expression. For 
example, a methylated DNA sequence can interfere with the binding of transcription 
factors such as E2F, NGFI-A or CREB (Iguchi-Ariga and Schaffner, 1989; 
Campanero et al., 2000; Weaver et al., 2004), thereby preventing transcriptional 
activation. While the consequence of DNA methylation s generally thought of as 
transcriptional silencing, methylation of repressor protein-binding sites can lead to 
increased gene expression. For example, the imprinted gene insulin-like growth factor 
2 (Igf2) can be activated if the upstream repressor sites are differentially methylated in 
the paternal allele (Eden et al., 2001).  
Secondly, methylated DNA might recruit proteins know  as methyl-CpG-
binding domain proteins (MBDs). These can recruit additional proteins, such as 
histone deacetylases (HDACs) and other chromatin remod ling complexes known to 
promote the formation of a condensed chromatin structu e that is inaccessible to 
transcription regulators (Jones et al., 1998; Nan et al., 1998; Wade et al., 1999; Fuks 
et al., 2003b). These methyl-CpG-binding domain proteins serve as readers and 
writers of epigenetic marks/signatures and provide a platform on which DNA 
methylation and chromatin modifications are carried out. There are 5 MBDs in 
mammals, namely, MeCP2, MBD1, MBD2, MBD3 and MBD4. Among these, 
MeCP2, MBD1, MBD4 bind to methylated DNA sequences through a conserved 
INTRODUCTION 
                                                                                                                                                    10                                                                                                                                                             
methyl-CpG binding domain (MBD). MBD3, which contains amino acid substitutions 
in the well-conserved methyl-CpG-binding domain, is involved in transcriptional 
repression as a component of a co-repressor complex irr spective of the DNA 
methylation status (Saito and Ishikawa, 2002).  
Besides the MBD family proteins, other proteins such as Kaiso, ZBTB4, and 
ZBTB38 are able to preferentially bind to methylated DNA in a sequence-specific 
manner through their zinc finger binding domains (Prokhortchouk et al., 2001; Filion 
et al., 2006). 
1.2.5  MeCP2 
1.2.5.1 Rett syndrome and MeCP2 
MeCP2 is the founding member of the methyl-CpG-binding protein family. MeCP2 
was firstly purified by Adrian Bird’s group from rat brain in 1992 (Lewis et al., 1992). 
It has been extensively studied since 1999 because patients with the 
neurodevelopmental disorder Rett syndrome harbor mutations in the MECP2 gene 
(Amir et al., 1999). It is estimated that one out of 10,000-20,000 females develops 
Rett syndrome (Percy, 2002). Newer reports suggest that Rett syndrome can also 
occur in males with much more severe symptoms (Hardwick et al., 2007). Rett 
syndrome is a progressive disease characterized by normal early development 
followed by mental retardation, loss of speech, stereotype hand movements and other 
neurological symptoms (Hagberg et al., 1983). It isthought that mutations in MECP2 
account for up to 96% of classic Rett syndrome cases (Shahbazian and Zoghbi, 2001).  
MeCP2 is also essential in mice: Mecp2-null animals exhibit phenotypic 
similarities of Rett syndrome; they show a period of n rmal postnatal development 
followed by hindlimb clasping, breath difficulties, reduced mobility, brain size and 
body weight, and death at around 8 weeks of age (Chn et al., 2001; Guy et al., 2001). 
Moreover, conditional deletion of the Mecp2 gene in cells of the neuronal lineage 
results in the same phenotype, indicating that the absence of normal MeCP2 function 
in neurons may be sufficient to cause disease. In addition, mice expressing a truncated 
MeCP2 protein (Mecp2308) that retains partial function display a less sever  
phenotype than that displayed by Mecp2-null mice (Shahbazian et al., 2002a). 
Furthermore, Mecp2 deletion in post-mitotic neurons leads to milder defects of RTT-
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like phenotypes, suggesting that mature neurons require continuous expression of 
MeCP2 to function properly (Chen et al., 2001). 
The mammalian central nervous system requires tightly adjusted MeCP2 levels 
for its proper function. MECP2 duplications in human have been found to cause a 
progressive postnatal neurological disorder with features of Rett syndrome. MECP2 
duplication in a girl produced effects with features of Rett syndrome in the presence 
of preserved speech (Ariani et al., 2004), while MECP2 duplication in a boy led to 
mental retardation and typical clinical features of Rett syndrome (Meins et al., 2005; 
Van Esch et al., 2005). Consistent with these findings, Mecp2 overexpression in 
transgenic mice results in severe neural defects in postnatal life (Collins et al., 2004). 
Mecp2-depleted neurons do not suffer severe irreversibl  damage since the restoration 
of Mecp2 can largely reverse the Rett syndrome phenotypes in mice (Luikenhuis et 
al., 2004). 
1.2.5.2 MeCP2 gene structure 
MeCP2, located at Xq28 in the human genome (Quaderi et al., 1994), comprises 4 
exons spanning a region of more than 75 kb in length. In mammals, MeCP2 is an 84 
kDa protein which is composed of three functional domains (Figure 2): the methyl-
CpG binding domain (MBD) (amino acids 78-160) which is responsible for 
recognizing and binding to methylated CpGs, the transcriptional repression domain 
(TRD) (amino acids 207-310) which recruits a corepressor complex including Sin3A 
and histone deacetylases, and a C-terminal region which contains a proline-rich 
protein interaction surface capable of binding to gr up II WW domains. MeCP2 
contains a nuclear localization signal (NLS: amino acid 255-271) which resides in the 
middle of the transcriptional repression domain andis responsible for transport of the 
protein into the nucleus (Chandler et al., 1999). 
MeCP2 encodes two splice variants (Kriaucionis and Bird, 2004; Mnatzakanian 
et al., 2004). MeCP2α, which contains a distinct N-terminus is more abundant than 
another isoform (MeCP2β) in mouse tissues and human brain. In addition, MeCP2β 
mRNA has an upstream open reading frame that inhibits ts translation, leading to 
lower translational efficiency. As a consequence, > 90% of the MeCP2 in mouse brain 
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corresponds to MeCP2α. Both protein isoforms are nuclear and colocalize with 
densely methylated heterochromatic foci in mouse cells (Kriaucionis and Bird, 2004). 
MeCP2 is ubiquitously expressed in normal tissues. Although MeCP2 shows low 
levels of expression during early stages of development, MeCP2 is widely expressed 
in embryonic and adult tissues, with high concentrations in brain, lung, pituitary and 
spleen, moderate in kidney and heart, and very low expression levels in liver, stomach 
and small intestine (Shahbazian et al., 2002b). 
 
Figure 2. Structure of the MeCP2 gene and mRNA. Alternative splicing for the MeCP2α 
isoform is shown in green and for the MeCP2β isoform in blue. The region encoding the MBD 
(Methyl-CpG Binding Domain) is depicted in cyan. The TRD (Transcription Repression Domain) 
is shown in red (Adopted from Kriaucionis and Bird, 2004). 
Generally, the affinity of MBD proteins for methylated DNA is 3-10-fold higher 
than for unmethylated DNA and may depend on sequence context (Fraga et al., 2003). 
In vitro binding assays revealed that MeCP2 is bound with hig affinity to DNA 
containing AT sequences (AT≥4) adjacent to methylated CpGs (Klose et al., 2005). 
1.2.5.3 MeCP2 function 
Several diverse functions have been reported for MeCP2, including transcriptional 
repression, activation of transcription, nuclear organization, and splicing. MeCP2 was 
initially thought of as a global repressor since it can bind to regulatory DNA 
sequences and exert strong transcriptional repression (Jones et al., 1998; Kokura et al., 
2001). However, transcriptional profiling of brains derived from Mecp2-null mice 
showed only subtle changes in gene expression compared with wild type mice (Tudor 
et al., 2002). Moreover, when RNA was isolated from the cerebellum of Mecp2 
mutant mice, similar expression profiles were obtained by microarray analysis (Jordan 
et al., 2007). At this step, the lack of obvious changes in gene expression indicated 
that the transcriptional changes in Mecp2 mutant mice might only occur in some 
subsets of cells and might not be detected when whole c rtex or hippocampus are 
processed.  
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MeCP2 also confers gene activation. Recent studies of  Mecp2-null mice showed 
that MeCP2 rather activates  than represses  hypothalamic gene expression (Chahrour 
et al., 2008). Although there remains the possibility that some genes are affected by 
one or more indirect interactions, chromatin immunoprecipitation (ChIP) assay 
proved the binding of MeCP2 to the promoter region of some activated genes 
(Chahrour et al., 2008).  
Because DNA methylation is important in the regulation of imprinted gene 
expression, it has been proposed that Mecp2-deficient mice might show dys-
regulation of imprinted gene expression due to altered chromatin configuration. 
Several imprinted genes, including Dlx5, Dlx6 and Ube3A, have been reported to 
show abnormal expression levels in the brain of Mecp2-null mice (Horike et al., 2005; 
Makedonski et al., 2005; Samaco et al., 2005). The reason for such dysregulation 
might be the loss of MeCP2-dependent chromatin looping on the imprinted allele.  
MeCP2 has also been ascribed a role as regulator of splicing. In the brain, 
MeCP2 works as a modulator of alternative splicing via an interaction with the RNA-
binding protein YB-1 (Young et al., 2005). The MeCP2-YB-1 complex is very 
sensitive to RNAse treatment, suggesting that this interaction requires RNA for its 
formation and stability. Microarray analysis of mRNA from cerebral cortex of RTT 
mutant mice (Mecp2308/Y) revealed altered splicing of some genes following loss of 
functional MeCP2.  
1.2.5.4 Post-translational modifications of MeCP2 
Using a candidate gene approach, brain-derived neurotrophic factor (Bdnf) was first 
identified as a direct target for MeCP2 in cultured neurons. It was found that MeCP2, 
together with the co-repressor molecule Sin3a, forms a complex to maintain the 
repressed state of the Bdnf gene (Chen et al., 2003; Martinowich et al., 2003). 
Treatment of cultured neurons with potassium chloride (KCl), which induces 
membrane depolarization and calcium influx through opening of L-type voltage- 
sensitive calcium channels, leads to MeCP2 phosphorylation at serine 421 in the rat 
(Zhou et al., 2006). Phosphorylation of this residue promotes MeCP2’s dissociation 
from DNA, as demonstrated by southwestern assays (Chen et al., 2003). Zhou and 
coworkers (Zhou et al., 2006) demonstrated that Calmodulin-dependent Protein 
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Kinase II (CaMKII) mediates the phosphorylation of MeCP2 at serine 421 and 
underpins activity-dependent BDNF transcription. Moreover, it was reported that 
MeCP2 phosphorylation at serine 80 in the rat is critical for the association of MeCP2 
with chromatin (Tao et al., 2009). Calcium influx in neurons elicits dephosphorylation 
at S80 and probably contributes to the dissociation of MeCP2 from the chromatin. All 
these data support the concept that phosphorylation may be part of a reversible 
mechanism for adjustable, neuronal-activity controlled, gene repression by MeCP2. 
 
1.3 The pituitary gland  
 
The pituitary gland, or hypophysis, is a small endocrine gland (pea-sized in the adult 
human male) located at the base of the brain. It isfunctionally connected to the 
hypothalamus by the median eminence via the pituitary stalk. Anatomically, the 
pituitary gland is composed of two lobes: the larger anterior pituitary 
(adenohypophysis) and the smaller posterior pituitary (neurohypophysis). In rodents, 
there is a third component, the intermediate lobe (pars intermedia) that is located 
between the adeno- and neurohypophses; in humans, the intermediate lobe is only a 
small rudimentary structure. The anterior pituitary receives neurohormonal signals 
(hypothalamic releasing factors/hormones via the median eminence), whereas the 
posterior pituitary is directly innervated by the hypothalamus, with nerve endings that 
release the so-called neurohypophysial hormones oxytocin and arginine vasopressin 
from cell bodies in the magnocellular division of the paraventricular nucleus. Whereas 
the hypothalamic hormones that reach the anterior pituitary do not enter the general 
blood stream, neurohypophysial oxytocin and vasopressin are secreted into the 
general blood stream and act at distal peripheral ogans such as the uterus and 
mammary glands (oxytocin-targets) and kidneys, liver, and heart (vasopressin-
targets).  
The anterior pituitary is derived from ectodermal ce ls in Rathke’s pouch to 
generate morphologically-distinct cell types: cortico ropes, thyrotropes, gonadotropes, 
somatotropes, and lactotropes. There is also a sixth cell type which is non-hormone 
producing, the folliculostellate cells. During development, under the control of 
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various pituitary specific transcriptional factors and growth factors, these endocrine 
cells arise in the following sequence: corticotropes, thyrotropes, gonadotropes, 
somatotropes, and lastly, lactotropes. Somatotropes con titute approximately 50% of 
the cell population, lactotropes (10-25%), corticotropes (10-20%), thyrotropes (10%), 
and gonadotropes (10%) (Horvath and Kovacs, 1988). Of particular interest in the 
context of this study is the corticotropes which produce pro-opiomelanocortin 
(POMC), which is then proteolytically cleaved to adrenocorticotrophic (ACTH), β-
endorphin and αMSH, as well as other small peptides whose function is still 
incompletely understood. 
 
Figure 3. Schematic diagram of the human pituitary. The pituitary gland is located at the base 
of the skull between the optic nerves. The anterior pituitary comprises 5 main cell types that 
synthesize and release (into the blood stream) the adenohypophyseal hormones 
adrenocorticotrophic (ACTH) (target: adrenal cortex), luteinizing hormone (LH) and follicle-
stimulating hormone (FSH) (gonads), growth hormone (GH) (skeletal and metabolic tissues), 
prolactin (PRL) (mammary glands), and thyroid-stimulating hormone (TSH) (thyroid). AVP and 
oxytocin are released from hypothalamic nerve terminals contacting the posterior lobe and then 
into the general circulation.  
  Rodent anterior pituitary (from now on, referred to simply as pituitary) cells, 
including corticotropes, proliferate and differentiate during postnatal development. 
Friend (Friend, 1979) showed that the weight of the rat pituitary increases more than 
3-fold during the first 10 days of life and doubles over the next 15 days. Pituitaries 
from adult rats weigh 5 times more than those of 25-day-old animals. Interestingly, 
the different pituitary cell types proliferate at different rates; they are first detectable 
in fetuses aged 15.5 days. While embryonic corticotropes arise from undifferentiated 
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cells, those produced postnatally derive from pre-existing corticotropes (Taniguchi et 
al., 2000; Taniguchi et al., 2002).  
 
1.4 Pomc gene 
1.4.1 Pomc gene structure and function 
The pro-opiomelanocortin (Pomc) gene, localized at chromosome 12 in mouse, 
encodes a cDNA comprising 1007 nucleotides spanning 3 exons and 2 introns. 
Computational analysis (CpGPlot, EMBOSS) and previous literature (Gardiner-
Garden and Frommer, 1994) revealed 2 CpG islands within the mouse Pomc gene 
locus: CpG island 1 (CGI 1), flanking the Pomc transcription start site and CpG island 
2 (CGI 2), approximately 5 kb downstream, encompassing the third exon of the Pomc 
gene. The Pomc gene is predominantly expressed in the anterior and intermediate 
lobes of the pituitary. Pomc mRNA is also detected in the hypothalamus (Gee et al., 
1983), amygdala, cortex, testes (Chen et al., 1984), lymphoid cells (Lolait et al., 
1986), adrenal medulla (Evans et al., 1983), ovaries, placenta (Chen et al., 1986) and 
some tumor tissues (Lacaze-Masmonteil et al., 1987; DeBold et al., 1988). The size of 
the mature POMC transcript in the pituitary is about 1200 nucleotides, while in the 
hypothalamus, POMC mRNA transcripts seem to be identical to pituitary except for 
longer poly(A) tails (Jeannotte et al., 1987). In testis, POMC-derived transcripts are 
about 400 bases shorter than those in the pituitary (Chen et al., 1984; Lacaze-
Masmonteil et al., 1987). This truncated POMC mRNA transcript contains no exon 1 
or exon 2 sequences, and is transcribed from the transc iption initiation site near the 
5’ end of exon 3. Since the peptide translated from this form of POMC mRNA lacks a 
signal peptide, it can not be secreted (Clark et al., 1990). Therefore, its role in 
peripheral tissues is unresolved. 
POMC is a 241-amino-acid precursor polypeptide, which is cleaved in a tissue- 
specific fashion by prohormone convertases to yield a variety of bio-active peptides, 
including α-melanocortin stimulating hormone (α-MSH), β-endorphin, β-lipotropin 
(β-LPH) and adrenocorticotropin (ACTH). There are eight potential cleavage sites 
within the POMC precursor and different tissues contain specific convertases to 
produce a variety of biologically-active peptides. In the anterior pituitary, ACTH and 
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β-lipotropin are the major cleavage products. In the int rmediate lobe, POMC can be 
cleaved into the following peptides: corticotrophin-like intermediate peptide (CLIP), 
γ-lipotropin (γ-LPH), β-endorphin, α-MSH and γ-melanophore stimulating hormone 
(γ-MSH). POMC-derived peptides play diverse roles in pathophysiology, including 
obesity, depression, skin pigmentation, adrenal development, and regulation of the 
HPA axis. In other tissues, including the hypothalamus, placenta and epithelium, all 
eight potential cleavage sites may be used to produce peptides responsible for energy 
homeostasis, pain, perception, melanocyte stimulation and immune responses.  
 
Figure 4. Mouse Pomc gene, mRNA, pro-hormone and peptides.The pro-opiomelanocortin 
(Pomc) gene encodes a cDNA comprising 1007 nucleotides spanning 3 exons and 2 untranslated 
introns. The Pro-POMC is a 241-amino-acid precursor polypeptide, which is cleaved in a tissue- 
specific fashion by prohormone convertases to yield a variety of bio-active peptides. In the 
corticotrope cells of the anterior pituitary, adrenocorticotropic hormone (ACTH) and β-lipotropin 
(β-LPH) are products under the control of corticotropin releasing hormone (CRH). In the 
intermediate lobe of the pituitary, alpha-melanocyte stimulating hormone (α-MSH), corticotropin-
like intermediate lobe peptide (CLIP), γ-lipotropin and β-endorphin are products generated under 
the control of dopamine. α- and γ-MSH are collectively referred to as melanotropin or intermedin.  
Anterior pituitary POMC synthesis and ACTH secretion are regulated by CRH 
released from neurohemal axon terminals in the median eminence of the 
hypothalamus. AVP, produced in parvocellular neurons of the hypothalamic 
paraventricular nucleus (PVN), acts synergistically with CRH to activate POMC 
transcription in the pituitary. CRH binds with high affinity to CRH-type 1 receptors 
(Vita et al., 1993; Timpl et al., 1998), thus stimulating cAMP production by adenylate 
cyclase (Giguere et al., 1982; Aguilera et al., 1983; Litvin et al., 1984; 
Grammatopoulos and Chrousos, 2002) and leading subseq ently to activation of 
protein kinase A (PKA) (Reisine et al., 1985; Kovalovsky et al., 2002). This is 
followed by an influx of extracellular calcium through L-type voltage-dependent 
calcium channels (Kuryshev et al., 1996). As a consequence, calcium calmodulin 
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kinase II (CaMKII) becomes activated (Kovalovsky et al., 2002). These signaling 
events ultimately converge on POMC transcription and ACTH secretion (von Dreden 
et al., 1988; Kovalovsky et al., 2002).  
1.4.2 Experience-dependent POMC methylation 
To date, the methylation status of POMC has been studied exclusively in human 
tissues. The human POMC gene contains two CpG island  (Gardiner-Garden and 
Frommer, 1994). The intronic POMC  promoter is located in the downstream CpG 
island and is barely expressed in most tissues. The upstream CpG island shows high 
tissue-specificity. Over-secretion of ACTH from non-pituitary tissues, resulting in 
severe Cushing’s disease, is thought to be due to activation of a (normally) tissue-
specific POMC promoter in ectopic tissues (Ye et al., 2005). The promoter contains a 
CpG island. The same study confirmed the causal relationship between DNA 
methylation and POMC gene expression. In ACTH-secreting tumors and POMC-
expressing DMS-79 cell lines, POMC is unmethylated at the pituitary-specific 
promoter region. In contrast, in non-ACTH-secretion tumors, this region is heavily 
methylated (Newell-Price et al., 2001). In addition, POMC is heavily methylated at 
the same region in a number of normal ACTH-non-exprssing tissues including: 
pancreas, spleen, lung, testes and peripheral blood leukocytes (Newell-Price et al., 
2001). In thymic carcinoid patients, hypomethylation n the 5’ promoter region of the 
POMC gene is negatively correlated with over-expression of the POMC mRNA 
transcript (Ye et al., 2005).  
POMC DNA methylation can be altered by environmental conditions. For 
example, in a neonatal model of obesity, bisulfite sequencing of DNA isolated from 
the hypothalamus revealed hypermethylation of CpG dinucleotides within two Sp-1- 
related binding sequences in the POMC promoter. These two sites are essential for the 
mediation of leptin and insulin effects on POMC expression. Accordingly, gain of 
methylation within Sp1-related binding sites correlat d with less activation of POMC 
expression by leptin or insulin signaling (Plagemann et al., 2009).  
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1.5 Goals of the thesis 
In both human and rodents, extensive research has shown that early-life experience 
has a profound impact on adult physiology and behaviour. Different environmental 
experiences in early life might contribute to the vulnerability for depression and 
anxiety later in life. However, the detailed mechanisms mediating these effects remain 
elusive. Using maternal separation as a paradigm of early life stress, the present work 
aimed to: 
 Examine neuroendocrine profiles in animals that had experienced stress (maternal 
separation) during the first 10 days of life 
 Analyze changes in Pomc methylation and gene expression 
 Investigate age-associated changes of the expression of Pomc mRNA in 
pituitaries from animals subjected to early life stre s 
 Examine whether the effects of maternal separation are expressed differently in 
the two sexes   
 Identify the molecular mechanisms underlying the long-term effects of maternal 
separation on altered Pomc expression 
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2 Materials and methods 
 
2.1 Materials 
2.1.1 Chemicals 
Consumable Supplier Consumable Supplier 
1kb DNA ladder Fermentas 3mm filter paper Wattman 
Agar Gibco Agarose (low-melting point) Gibco 
Agarose (universal) Peqlab  Ampicillin Roth 
Antibiotic/antimycotic Gibco Boric acid Biomol 
Bradford assay Biorad Bromophenol blue Biorad 
Bovine serum albumin (BSA) Sigma Chloroform Roth 
Chloroform (RNase free) Merck Coomassie blue Biorad 
Developing emulsion (slides)  Kodak Developing solution (film) Kodak 
Developing solution (slides)  Kodak DMSO Sigma 
dNTPs (set of 4)  Fermentas DTT Sigma 
Dulbecco’s minimum essential 
medium (DMEM) 
Gibco EDTA Sigma 
Ethanol  Merck Ethidiumbromide Biomol 
Ficoll 400  Sigma Fixing solution (films) Kodak 
Fixing solution (slides)  Kodak bovine serum Gibco 
Formaldehyde  Merck Formamide Sigma 
L-Glutathione reduced  Sigma Glutathionine Sepharose Amersham 
Glycerine  Sigma Glycerol  Biomol 
Glycogen Fermentas Guanidine thiocyanate Merck 
IPTG  Fermentas Isoamylalkohol  Merck 
β-mercaptoethanol  Merck Methanol Merck 
Oligonucleotides  MWG /Sigma Optimem medium Gibco 
Paraformaldehyde  Sigma Phosphate buffered saline 
(PBS) 
Gibco 
Phenol  Appligene Ponceau Sigma 
2-propanol Merck 2-propanol (RNase free) Merck 
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Protein marker Fermentas Poly(d(I-C)) Roche 
Potassium chloride Sigma SDS Biomol 
Siliconising fluid Merck Sodium acetate Merck 
TEMED Sigma Tris Riedel-de Haen 
Triton X-100 Roth Trypsin Gibco 
Tryptone  Roth X-Gal Sigma 
Yeast extract Gibco Zeocin Invitrogen 
γ32P-ATP Amersham 32P-dCTP Perkin Elmer 
 
2.1.2 Restriction endonucleases 
Enzyme Supplier Enzyme  Supplier 
BamHI Fermentas BglII Fermentas 
EcoRI Fermentas EcoRV Fermentas 
HindIII Fermentas NcoI Fermentas 
PstI Fermentas SacI Fermentas 
SmaI Fermentas XbaI Fermentas 
XhoI Fermentas   
 
2.1.3 Modifying enzymes 
Enzyme Supplier Enzyme Supplier 
SssI CpG methylase NEB T4-DNA-Ligase Fermentas 
T4 DNA polymerase  Fermentas CIAP Fermentas 
DNA pol. I, Klenow fragment  NEB DNA polymerase (Taq.) Fermentas 
DNA polymerase (Pfu) Fermentas DNaseI  Fermentas 
Proteinase K  Boehringer 
Mannheim 
Proteinase K (RNase free) Sigma 
RNase  Sigma RNase inhibitor  Fermentas 
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2.1.4 Antibodies 
2.1.4.1 Primary antibodies against mouse  
Antibody Epitope Host Supplier 
Anti-flag M2 (monoclonal) Mouse Sigma 
Anti-acetyl-histone 
H3 
ARTKQTATK*APRKQLC 
K* is acetylated 
Rabbit Millipore 
Anti-H3K9me2 Rme2KSTG Rabbit Millipore 
Anti-total MeCP2 C-PRPNREEPVDSRTP Rabbit Upstate 
Anti-total MeCP2 NH2-CSMPRPNREEPVDSRTPV-C Rabbit Home-made 
Anti-pS421 MeCP2 C-MPRGG pSLES Rabbit Gifted by Greenberg’s 
lab (Zhou et.al., 2006) 
Anti-pS438 MeCP2 NH2-CMPRGGPpSLES-C Rabbit Home-made 
Anti-pS80 MeCP2 Not available Rabbit Gifted by Jifan Tao’s 
lab (Tao et.al., 2009) 
Anti-pS97 MeCP2 EASApSPKQR Rabbit Home-made 
Anti-POMC Amino acids 6-266 of Human POMC Mouse DAKO 
Anti-total CaMKII Amino-terminus of human CaMKII Rabbit Cell Signaling 
Anti-phospho 
(Thr286)-CaMKII 
Synthetic phosphopeptide flanking 
Thr286 of human CaMKII 
Rabbit Cell Signaling 
Anti-RNA Pol II CTD  RNA Pol II CTD repeat YSPTpSPS Rabbit Home-made 
Anti-HDAC1 EEKPEAKGVKEEVKLA Rabbit Abcam 
Anti-HDAC2 C-SGEKTDTKGTKSEQLSNP Rabbit Abcam 
Anti-HDAC4 Not available Rabbit Abcam 
Anti-DNMT1 EKDDREDKENAFKR Mouse Acris 
Anti-DNMT3a Bacteria expressed HIS-tag DNMT3a Mouse Acris 
Anti-DNMT3b Bacteria expressed HIS-tag DNMT3b Mouse Acris 
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2.1.4.2 Secondary antibodies 
 
Antibody  Epitope Host Supplier 
Anti-rabbit (594) rabbit IgG Goat Perbio 
Anti-mouse (488) mouse IgG Goat Santa Cruz 
Anti- rabbit (HRP) rabbit IgG Goat Sigma 
 
2.1.5 Vectors 
Vector Supplier 
pCpGL-Basic 
pCpGL-Pomc 
pCpGL-Pomc-∆CpG6-8 
pCpGL-Pomc-∆Dis-prom 
Gifted by Michael Rehli (Klug and Rehli, 2006) 
Own construct 
Own construct 
Own construct 
pRK7-Flag 
pRK7-Flag-MeCP2 
pRK7-Flag-MeCP2-∆C 
pRK7-Flag-S438A MeCP2 
pRK7-Flag-S97A MeCP2 
Gifted by Anke Hoffmann (Hoffmann and Spengler, 2008)  
Own construct 
Own construct 
Own construct 
Own construct 
pGEM-T  Promega 
His-tag MeCP2 1-250 Gifted by Adrian Bird (Kriaucionis and Bird, 2004) 
CaMKII 1-280 Gifted by Anthony R Means  (Planas-Silva and Means, 1992) 
CaMKII T286D Gifted by Gina Turrigiano  (Pratt et al., 2003) 
CaMKII Gifted by Anthony R Means  (Planas-Silva and Means, 1992) 
MBD1 Own construct 
MBD2 Gifted by Samson T. Jacob (Majumder et al., 2006)   
MBD3 Gifted by Samson T. Jacob (Majumder et al., 2006)  
GST-MeCP2 Own construct 
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2.1.6 Plastics 
Consumable Supplier Consumable Supplier Consumable Supplier 
Filtertips Sarstedt PCR plates/caps  ABgene Cell culture plates Greiner 
Pipette tips Sarstedt Scalpels Merck Micro test plates Greiner 
Cuvette 1mm Biorad X-ray cassette Kodak   
 
2.1.7 Molecular biology kits 
Consumable Supplier Consumable Supplier 
NucleoSpin PCR purification 
Kit 
Macherey-
Nagel 
96-PCR purification plate Macherey-
Nagel 
Protease inhibitor cocktail Sigma Phosphatase inhibitor cock- 
tail 1+2 
Sigma 
Magna ChIP G kit Millipore Montage SEQ96 sequencing  
reaction cleanup kit 
Millipore 
BigDyeTerminator v3.1 Cycle 
sequencing kit 
ABI NucleoSpin plasmid quick- 
prep 
Macherey 
Nagel 
RNeasy Qiagen Lipofectamine reagent Invitrogen 
Superscript II RT Kit Invitrogen Picogreen DNA quantifica- 
tion reagent 
Molecular 
probes 
Bio-spin 6 columns Biorad LightCycler FastStart DNA 
master SYBR Green I 
Roche 
TRIzol® Reagent Invitrogen pGEM-T vector system Promega 
 
2.1.8 Cell lines  
Name Derived tissue Morphology Supplier Reference 
AtT-20/D16v-
F2 
Mouse pituitary 
epithelial-like 
tumor cell line 
epithelial ATCC (Buonassisi et al., 
1962) 
LLC-PK1 porcine kidney epithelial ATCC (Perantoni and 
Berman, 1979) 
Neuro2a Murine 
neuroblastoma 
Neuronal ATCC (Olmsted et al., 
1970) 
AtT20 (v1bR) Mouse pituitary 
epithelial-like 
epithelia Gifted by Dr. (Serradeil-Le Gal 
et al., 2007) 
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tumor cell line Eric Clauser 
INSERM U970 
 
2.1.9 Bacterial strains 
DH5α from Invitrogen 
PIR1 from Invitrogen 
2.1.10 Primer sequences 
2.1.10.1 Primers for RT-PCR 
Oligo name Sequence Region Product 
size (bp) 
POMC F, 5’-GAA GAT GCC GAG ATT CTG CT-3’ 
R, 5’-TTT CAG TCA GGG GCT GTT C-3’ 
Exon2/3 221 
HPRT1 F, 5’-ACC TCT CGA AGT GTT GGA TAC AGG-3’ 
R, 5’-CTT GCG CTC ATC TTA GGC TTT G-3’ 
Exon7/9 168 
GAPDH F, 5’-CCA TCA CCA TCT TCC AGG AGC GAG-3’ 
R, 5’-GAT GGC ATG GAC TGT GGT CAT GAG-3’ 
Exon3/4 
+5 
326 
MeCP2 
 
DNMT1 
F, 5’-ACA GCG GCG CTC CAT TAT C-3’ 
R, 5’-CCC AGTTAC CGT GAA GTC AAA A-3’ 
F, 5’-GGA AGG CTA CCT GGC TAA AGT CAA G-3’ 
R, 5’-ACT GAA AGG GTG TCA CTG TCC GAC-3’ 
Exon3/4 
 
Exon2/3 
237 
 
216 
Oligo-dT 5’-TTT TTT TTT TTT TTT TTT TT-3’   
 
2.1.10.2 Primers for bisulfite sequencing 
Primer 
 pair 
Sequence Region Product  
size (bp) 
Prom-core  F, 5’-GTT TTT TAG GTA GAT GTG TTT TG-3’ 
R, 5’-CTA CTC TTA ACC TCT TTT CTC TTC-3’ 
Core  
promoter 
203 
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Prom-distal  5’-TTT TTT TAT TAT TGG GGA AAT TT-3’ 
5’-CAA AAC ACA TCT ACC TAA AAA A-3 
Distal  
promoter 
290 
 
5’-UTR 5’-TTT TTA TTT AGA TTA TTT TGT TAG TTT AGT-3’ 
5’-TAA TAT CTT ATA AAA CCA AAA TCT CAA TTC-3 
5’ UTR 283 
Exon3 
 
5’-TTA TTA GGT TTG GAG TAG GTT TTG G-3’ 
5’-ACA CCC TCA CTA ACC CTT CTT ATA-3’ 
Coding  
region 
204 
 
2.1.10.3 Oligonucleotides for EMSA  
Oligo name sequence 
EMSA 1 
wild type 
For    5’-GTGGGAAATCTGCGACATAACAAATCC-3’ 
Rev   3’-CCTTTAGACGCTGTATTGTTTAGGGTG-5’ 
EMSA1 
AT all Mut 
For    5’-GTGGGACACCTGCGACACACCAGACCC-3’ 
Rev   3’-CCTGTGGACGCTGTGTGGTCTGGGGTG-5’ 
EMSA1 
AT2+3 Mut 
For    5’-GTGGGAAATCTGCGACACACCAGACCC-3’ 
Rev   3’-CCTTTAGACGCTGTGTGGTCTGGGGTG-5’ 
EMSA1 
AT3 Mut 
For    5’-GTGGGAAATCTGCGACATAACAGACCC-3’ 
Rev   3’-CCTTTAGACGCTGTATTGTCTGGGGTG-5’ 
EMSA2 
wild type 
For    5’-GTGGACGCACATAGGTAATTCCACTCCGATCT-3’ 
Rev   3’-CTGCGTGTATCCATTAAGGTGAGGCTAGAGTG-5’ 
EMSA2 
CpG8 Mut 
For    5’-GTGGACGCACATAGGTAATTCCACTCTGATCT-3’ 
Rev   3’-CTGCGTGTATCCATTAAGGTGAGACTAGAGTG-5’ 
EMSA2 
CpG all Mut 
For    5’-GTGGAAGCACATAGGTAATTCCACTCTGATCT-3’ 
Rev    3’-CTTCGTGTATCCATTAAGGTGAGACTAGAGTG-5’ 
EMSA2 
AT Mut 
For    5’-GTGGACGCACATAGGTCAGTCCACTCCGATCT-3’ 
Rev   3’-CTGCGTGTATCCTGTCTGGTGAGGCTAGAGTG-5’ 
Negtive 
control 
For    5’-GTGGCCTCCGCGCTTTCCAGGCAGATGTGCC -3’ 
Rev   3’-CGGAGGCGCGAAAGGTCCGTCTACACGGGTG-5’ 
Positive  
control 
For    5’-GTGATATGGTTTCAGAATAAGCGCTCTAAGTTTAAGAAATT-3’ 
Rev   3’-TATACCAAAGTCTTATTCGCGAGATTCAAATTCTTTAAGTG -5’ 
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2.1.10.4 Primers for ChIP assay 
Oligo name Sequence 
POMC-prom-F 5’-AAT CTG CGA CAT AAC AAA TCC CC-3’ 
POMC-prom-R 5’-AGA ACT GGA CAG AGG CTT AGC GT-3’ 
POMC-exon3-F 5’-GCT CTT CAA GAA CGC CAT C -3’ 
POMC-exon3-R 5’-TGA AGA TCA GAG CCG ACT GT -3’ 
POMC-CpGL-F 5′-GAG CAA ACA GCA GAT TAA AAG GAA T -3′ 
POMC-CpGL-R 5′-GAT CGG AGT GGA ATT ACC TAT GTG-3′ 
 
2.1.10.5 Primers for vector construction and sequencing 
Oligo name Sequence 
POMC-pro-Luc-forward 5’-GGA TCC TGA GAT TTT GGT TTC ACA AGA TAT-3’ 
POMC-pro-Luc-reverse 5’-AAG CTT GTG GCC TCT CTT AGT CAC TGC T-3’ 
MeCP2 mut S438A-F 5’-CCC GAG GAG GCC GAC TGG AAA GCG ATG GC-3’ 
MeCP2 mut S438A-R 5’-GCC ATC GCT TTC CAG TCG GCC TCC TCG GG-3’ 
MeCP2 S97A Seq-F 5’-GAA GCC TCG GCT CGA CCC AAA CAG CGG-3’ 
MeCP2 S97A Seq-R 5’-CCG CTG TTT GGG TCG AGC CGA GGC TTC-3’ 
MeCP2-seq-1604-R 5’-ATC CAC AGG CTC CTC TCT GTT-3’ 
MeCP2-seq-1612-F 5’-AAA GGT GGG AGA CAC CTC CT-3’ 
MeCP2 mut S97A-F 5’-GAA GCC TCG GCT CGA CCC AAA CAG CGG-3’ 
MeCP2 mut S97A-R 5’-CCG CTG TTT GGG TCG AGC CGA GGC TTC-3’ 
T7 5’-TAA TAC GAC TCA CTA TAG GG-3’ 
Sp6 5’-CAT TTA GGT GAC ACT ATA G-3’ 
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2.2 Methods 
2.2.1 Animals and maternal separation 
2.2.1.1 Animals 
Pregnant C57BL/6N mice were obtained from Charles River Laboratory (Charles 
River, Sulzfeld, Germany), upon arrival they were housed under standard conditions 
at the animal facility of Max-Planck Institute of Psychiatry [temperature controlled 
(21°C) environment and 12h light:12h dark cycle (lights on at 06:00)]. Both male and 
female pups were used in this experiment. All procedur s were approved by the 
Regierung von Oberbayern and were accordance with European Union Directive 
86/609/EEC.  
 
2.2.1.2 Separation paradigm 
Maternal separation was used as early life stress (ELS) paradigm. Before pups were 
born, all dams were randomly assigned to one of the groups: control group (Ctrl) and 
early life stress group (ELS). For all groups, the day of birth was considered as 
postnatal day (PND) 0. For the ELS group, the pups were removed from their dam 
daily for 3 hours for 10 consecutive days from PND1-10. The pups were placed in a 
clean cage with a heat pad (~32°C) to maintain body temperature. During this period, 
there is no physical contact between the pups and their dam. After 3 hours separation, 
the pups were placed back in the home cage with their mother. For the control group, 
litters remained undisturbed with their mother throughout the whole experiment.  In 
both groups, pups remained with their mother until PND21, and then they were 
housed in sex-matched group with 3−5 mice per cage. 
2.2.1.3 Neuroendocrine measurements 
For measurements of corticosterone and ACTH in plasma, commercial 
radioimmunoassay (RIA) kits (DRG diagnostics, Marburg) were used according to 
the manufacture’s protocol.  
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2.2.2 DNA analysis 
2.2.2.1 DNA extraction  
Mouse pituitary DNA was purified by phenol-chloroform extraction. 500 µl lysis 
buffer (1% SDS, 5 mM EDTA, 100 mM NaCl, 0.5 mg/ml freshly prepared proteinase 
K (Roche #3115879) and 10 mM Tris-HCl, pH8.0) was added to a 1.5 ml reaction 
tube containing pituitary tissue, then the solution was incubated overnight at 56 °C. 
On the following day, the clear lysate was cooled down on ice for 30 minutes and 200 
µl of salt solution (4.21 M NaCl, 0.63 M KCl, 10 mM Tris-HCl (pH 8.0)) was added. 
The tube was incubated on ice for 1 hour and centrifuged for 10 minutes at maximum 
speed (14,000 g) in a cooled microfuge. The supernatant was transferred to a fresh 
tube and 1 volume of cold Phenol /Chloroform was added. The tube was vortexed for 
1 minute and centrifuged for 2−3 minutes at maximum speed at 4 °C. The upper 
aqueous phase was transferred carefully without touching the inter-phase to a fresh 
tube, 2–2.5 volume of pure ethanol and 1 µl glycogen (10 mg/ml) was added, then 
DNA was precipitated overnight at -20 °C. After centrifugation 15 minutes at 
maximum speed in a precooled centrifuge, the pellet was washed with 70% ethanol. 
The pellet was air dried for 5 minutes at 60 °C.  25-50 µl of TE (10mM Tris-Cl, pH 
7.5, 1mM EDTA) buffer or distilled water was added to each sample. PicoGreen 
reagent (Molecular Probes) was used to quantify DNA concentration.  
2.2.2.2 PCR reaction  
Standard PCR was performed in a Biometra T-Gradient thermocycler (Biometra, 
Germany) with Fermentas Taq polymerase. 
If not indicated otherwise, the following PCR conditions were used: 
Step Temperature Time  Cycles PCR mix 
Initial 
denaturation 
95 °C 5 mins 1 2 µl template 
Denaturation 95 °C 1 min  2.5 µl 10×reaction buffer 
Annealing 56 °C 1 min 35 1.5 µl dNTPs (10 mM each) 
Elongation 72 °C 1 min  1.5 µl forward primer (10 pmol/µl) 
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Final elongation 72 °C 10 mins 1 1.5 µl reverse primer (10 pmol/µl) 
 
Storage 
 
10 °C 
 
pause 
 3 µl MgCl2  (25 mM)  
1U Taq polymerase 
add water to 25 µl 
 
Table 1. Standard PCR temperature profile and PCR mix. 
 
2.2.2.3 Agarose gel electrophoresis 
Agarose gel electrophoresis was used to analyse the quality of DNA and to separate 
fragments by size. Depending on the size of the DNA molecules, agarose solutions 
ranged from 0.8 to 2% (w/v) in 1 x TBE buffer (90 mM Tris, 90 mM Boric acid, 2 
mM EDTA). Ethidium bromide was added to a final cone tration of 0.25 µg/µl. The 
samples to be analyzed were mixed with 1x loading dye (6x loading dye: 40% v/v 
sucrose, 0.25% xylene cyanol, and 0.25% bromophenol blue). The voltage applied 
depended on desired separation, gel strength and chamber sizes. In general, the 
voltage applied was between 4−5 V/cm. As size standard, a 1kb DNA ladder 
(Fermentas) was used. The DNA or RNA was visualized on a UV transilluminator. 
2.2.2.4 Recovery of DNA from agarose gels  
The desired DNA band was cut out from an 0.8% low melting point agarose gel on a 
UV transilluminator and transferred into a 1.5 ml tube. The Macherey-Nagel PCR 
purification kit was used to recover the DNA fragment from the gel. 100 µl of NT 
buffer was added to the tube and incubated at 65 °C on a thermomixer (Eppendorf, 
Germany) with gentle shaking until gel melting. The mixture was transferred to a 
PCR purification column and processed according to manufacturer’s instructions. . 
2.2.2.5 Bisulfite sequencing 
Genomic DNA (200 ng) isolated from mouse pituitary was digested overnight with 
EcoRI, sodium bisulfite converted (Qiagen EpiTect Bisulfite kit) and aliquots used for 
PCR reactions. Products were cloned into the pGEM-T vector (Promega), and 
recombinant clones were picked to perform colony PCR. Products were checked for 
correct insert size by gel electrophoresis. After purification of PCR products 
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(NucleoFast PCR Cleanup Plate, Macherey-Nagel, Germany), BigDye sequencing 
reactions were performed. For each amplicon, at least 24 independent recombinant 
clones were analyzed on an ABI Prism 3700 capillary sequencer. 
 
 
Figure 5. Bisulfite sequencing flowchart. Genomic DNA from mouse pituitary was overnight 
restriction enzyme digested and then bisulfite converted. Treatment of DNA with bisulfite 
converts cytosine (C) residues to uracil (U), but leaves 5-methylcytosine residues unaffected. In 
the following PCR reaction, the uracil will appear as a thymidine (T). PCR products were then 
subcloned into pGEM-T vector. Recombinant clones, identified by color selection, were picked as 
template in the colony PCR. For each amplicon, at le st 24 independent recombinants were 
analyzed on an ABI 3730 capillary sequencer. Sequencing files were assembled by the computer 
program--Bioedit and methylation patterns of each anim l were deduced. 
 
2.2.2.6 Chromatin immunoprecipitation (ChIP) 
Chromatin immunoprecipitation experiments were performed with AtT20 cells and 
mouse pituitaries to investigate the binding of MeCP2 at the Pomc promoter. For in 
vivo ChIP, frozen pituitary tissue was first chopped up using scissors and then washed 
with 1 ml 1×PBS containing protease inhibitor (1:100 dilution, Sigma). AtT20 cells or 
pituitary tissues were incubated for 10 minutes at 37 °C in the presence of 1% 
formaldehyde. Formaldehyde treatment was quenched by a dition of glycine to a final 
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concentration of 125 mM. The chromatin immunoprecipitation protocol was based on 
the Upstate Biotechnology ChIP Kit (Magna ChIP G, Millipore) protocol with the 
following modifications: samples were sonicated for 12 cycles of: [30 seconds "ON" / 
30 seconds "OFF"] with the Bioruptor TM from Diagenode (cat # UCB-200) in a wet 
ice bath. After sonication, 5 µl of the sheared material was loaded on a 1% agarose gel 
to check fragment sizes. The DNA smear on the gel should range between 200 bp and 
1000 bp. DNA concentrations of the chromatin samples were determined with a 
SmartSpec Plus spectrophotometer (Bio-Rad). The sonicated samples w re either 
subjected to immunoprecipitation or stored at -20 °C until further use. Chromatin 
samples 5 OD were then subjected to immunoprecipitation using antibodies specific 
to the MeCP2 C-terminus or phospho-RNA pol II according to the Upstate ChIP kit 
protocol. To reduce unspecific binding in the immunoprecipitation, antibodies were 
pre-incubated with chromatin DNA on a rotating platform in the cold room overnight, 
and the Dynabeads Protein G (Invitrogen) were added on the following day and 
incubated for an additional 1 hour in the cold room with rotation. After reverse 
crosslinking, protein digestion, and DNA purification, immunoprecipitates were 
dissolved in 50 µl TE buffer and subjected to standard or real-time PCR. 
2.2.2.7 Sequential ChIP 
For sequential ChIP assays, the initial ChIP was performed with the indicated 
antibodies, chromatin was eluted with 50 µl dithiothreitol (DTT) (10 mM), and a 
second ChIP was then carried out. Amplified products were quantified by real-time 
PCR. The relative binding of the immunoprecipitated proteins at the Pomc locus was 
calculated from real-time PCR data. 
 
2.2.3 RNA analysis  
2.2.3.1 RNA isolation 
Total RNAs from pituitary tissues or cell lines were isolated using the TRIzol reagent 
(Invitrogen). All plastic and glassware used was rinsed with water containing 0.05% 
diethypyrocarbonate (DEPC) and autoclaved before use to inactivate RNAses. All 
experiments were performed on ice. Pituitary tissue or cell lines were homogenized 
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in 1 ml of TRIzol reagent. The homogenized samples w re incubated for 5 minutes at 
room temperature to permit complete disruption of nucleoprotein complexes. 0.2 ml 
of chloroform was added to the sample per 1 ml TRIzol reagent. Tubes were shaken 
vigorously by vortexing for 15 seconds and incubated at room temperature for 2−3 
minutes. Then all the samples were subjected to centrifugation at no more than 
12,000×g for 15 minutes at 4 °C. RNA stays exclusively in the aqueous phase. The 
aqueous phase was transferred to a fresh tube, and 0.5 ml of isopropyl alcohol (2-
propanol) was added per 1 ml of TRIzol reagent. Samples were incubated at room 
temperature for 10 minutes and centrifuged at no more than 12,000×g for 10 minutes 
at 4 °C. The supernatant was entirely discarded. The RNA pellet was washed once 
with 75% ethanol, adding at least 1 ml of 75% ethanol per 1 ml of TRIzol Reagent. 
Then the samples were mixed by vortexing and centrifuged at no more than 7,500×g 
for 5 minutes at 4 °C. RNA pellets were air dried for 5−10 minutes and dissolved in 
30 µl of DEPC-treated water. RNA concentrations were measured by RiboGreen. 
2.2.3.2 cDNA synthesis and subsequent gene-specific PCR  
Synthesis of cDNAs was carried out in 20 µl reaction volume. Total RNA (200 ng) 
isolated from mouse pituitary or cell lines was subjected to reverse transcription in the 
presence of 1 µl oligo (dT) (100 pm), 1.5 µl dNTP (10 mM each) mix and filled up 
with distilled water to 12 µl. Then the mixture was heated to 65 °C for 5 minutes and 
quick chilled on ice. The contents of the tube were collected by brief centrifugation. 
5× First-Strand buffer and 0.1M DTT were added to the tube, and then the samples 
were incubated at 42 °C for 2 minutes. In the next step, either 1 µl (200 units) of 
Superscript II RT transcriptase or 1 µl water for the negative control was added to the 
tube and then all the samples were incubated at 42 °C for 50 minutes. Finally, the 
reaction was terminated by heating at 70 °C for 15 minutes. The cDNA was used as 
template for amplification in PCR reactions. 
2.2.3.3 Quantitative PCR analysis 
Pomc mRNA expression level in the pituitary was analyzed by qRT-PCR, using the 
LightCyclerR FastStart DNA MasterPLUS SYBR Green I reagent (Roche 
Diagnostics GmbH, Germany). All experiments were performed according to 
manufacturer’s instructions. Reaction volumes were adjusted to 10 µl in each 
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experiment and contained 5 µl of distilled water, 0.5 µl of forward primer (10 
pmol/µl), 0.5 µl of reverse primer (10 pmol/µl) and 5x PCR-Mix (prepared by adding 
14 µl of reagent 1a to 1b from the Roche kit). Prime s used for qRT-PCR were 
designed across exons to avoid genomic DNA contamintio . The primers for POMC, 
MeCP2, DNMT1 and the housekeeping genes glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) and hypoxanthine guanine phosphoribosyl transferase 1 
(HPRT1) were listed in the previous parts. Experiments were performed in triplicates 
on the LightcyclerR 2.0 instrument (Roche Diagnostics GmbH) under the following 
PCR conditions: initial denaturation: 40 cycles of denaturation, annealing, and 
elongation (see Table 2 reaction conditions in the LightCyclerR for POMC, MeCP2 
and the housekeeping genes GAPDH and HPRT1 for reaction conditions). 
Fluorescence was assessed each cycle after the elongation phase. At the end of each 
run, a melting curve (50−95°C with 0.1 °C/sec) was generated to asses linearity of the 
amplification process. Crossing points (Cp) were calcul ted with the 
LightCyclerRSoftware 4.0 (Roche Diagnostics GmbH, Germany) using the absolute 
quantification fit-points method. Threshold and noise band were set in all compared 
runs to the same level. Relative gene expression was determined by the 2-∆CT method 
(Livak and Schmittgen, 2001) using the real PCR effici ncy calculated from an 
external standard curve. Cp was normalized to the housekeeping genes GAPDH and 
HPRT, respectively, and values calculated relative o the expression mean of each 
group. 
 
 
genesene Preincubation Denaturation Annealing Elongation 
Pomc 95 °C/10 min 95 °C/10 sec 56° C/5 sec 72 °C/8 sec 
Mecp2 95 °C/10 min 95 °C/10 sec 56° C/5 sec 72 °C/10 sec 
Dnmt1 95 °C/10 min 95 °C/10 sec 61°C/5 sec 72 °C/10 sec 
Gapdh 95°C/10 min 95 °C/10 sec 65 °C/5 sec 72 °C/13 sec 
Hprt1 95 °C/10 min 95°C/10 sec 57 °C/5 sec 72° C/8 sec 
 
Table 2. Amplification conditions of qRT-PCR 
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2.2.4 Plasmids 
2.2.4.1 Standard and parental plasmids 
pCpGL-Basic vector (graciously gifted by Michael Rehli, University Hospital 
Regensburg, Germany) was created by replacement of the enhancer/promoter region 
(PstI/NheI fragment) of the CpG-free plasmid pCpG-mcs (Invivogen, San Diego, CA) 
to a short CpG-free linker (5’-CTG CAG GAC TAG TGG ATC CAG ATC TTA 
AGC TTA GTC CAT GGA CAA TTG CTA GC-3’) containing several restriction 
sites. A CpG-free luciferase coding region was released from pMOD-LucShS 
(Invivogen) by digestion with MfeI (blunted using Klenow polymerase) and NcoI, 
and subcloned into NheI (blunted) and NcoI digested, linker ligated CpG-free 
backbone. The CpG-free luciferase vector containing R6K origin of replication was 
maintained in E.coli PIR1 cells (Invitrogen, Karlsruhe, Germany). This bacterial 
strain was grown in low salt LB medium (Tryptone, 10 g/l; yeast extract, 5 g/l; NaCl, 
5 g/l and pH 7.0 adjusted by NaOH) supplied with 25 µg/ml of Zeocine (Invitrogen) 
as antibiotics.  
pRK7-FLAG vector was created by cloning the oligonucleotides encoding the 
FLAG-epitope into the HindIII and BamHI digested pRK7 vector. These 
oligonucleotides encode for the short hydrophilic 8 amino acid (aa) peptide Asp-Tyr-
Lys-Asp-Asp-Asp-Asp-Lys. This epitope is likely to be located on the surface of a 
fusion protein due to its hydrophilic nature and, therefore, accessible to antibodies. 
The small size limits interference with the fusion protein’s function and 
transportation. 
2.2.4.2 Reporter constructs 
pCpGL-Pomc luciferase vector contains the promoter region of the mouse Pomc gene. 
A fragment spanning 550 bp of the mouse Pomc gene was amplified from genomic 
DNA isolated from the mouse corticotrope cell line AtT20 by PCR. The primers used 
for this PCR reaction contained a BamHI site in the forward primer and a HindIII site 
in the reverse primer. The PCR product was first cloned into pGEM-T (Promega) 
vector and verified by sequencing. The Pomc promoter fragment was then released 
from the pGEM-Pomc vector by BamHI and HindIII double digestion and purified on 
an agarose gel.  CpGL-basic vector which contained a CpG free backbone was also 
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double digested with BamHI and HindIII and dephosphorylated by adding 1U of calf 
intestinal alkaline phosphatase (CIAP) to avoid recircularization of the cloning vector. 
After gel purification of the backbone vector, the Pomc promoter fragment was 
ligated into the BamHI/HindIII site of pCpGL-Basic vector.  
pCpGL-Pomc-∆CpG6-8 containing a deletion of CpG residues 6−8 was 
generated by insertion of a BglII/HindIII fragment of previously described pCpGL-
Pomc into the BglII/HindIII site of the pCpGL-basic vector. pCpGL-Pomc-∆Dis-
prom vector containing only the proximal Pomc promoter was obtained by cloning a 
PstI/HindIII fragment of previously described pCpGL-Pomc into the PstI/HindIII site 
of the pCpGL-basic vector. 
2.2.4.3 Expression vectors 
The MeCP2 expression vectors (graciously gifted by Adrian Bird, University of 
Edinburgh, UK) consist of the mouse MeCP2_alpha variant in pRL-SV40 (Promega) 
and of a cDNA for the first 205 amino acids of human MeCP2 with a C-terminal His-
tag in the pet30b vector (Novagen), respectively. N-terminal Flag-tagged forms of 
different MeCP2 constructs were obtained by PCR-cloning of wild type (F; aag gga 
tcc gcc gcc gct gcc gcc acc gc, R; tct gat atc ctc agc taa ctc tct cgg tc) or of a form 
deleted of the 45 C-terminal amino acids of MeCP2 (F; aag gga tcc gcc gcc gct gcc 
gcc acc gc, R; tct gat atc ctc agc taa ctc tct cgg t ) into the BamHI and EcoRI sites of 
pRK7-Flag (Hoffmann et al., 2006). The MeCP2 riboprobe (nt 612–1,604; Acc. No. 
NM_010788) contains the conserved sequence within exons 3 and 4 of the mouse 
Mecp2 gene. A corresponding PCR-product (F; aaa ggt ggg aga cac ctc ct, R; tcc aca 
ggc tcc tct ctg tt) was cloned in the pGEM-T vector (Promega) and antisense 
riboprobes were generated as previously described (Dragich et al., 2007). Expression 
vectors for MBD2 and MBD3 (graciously gifted by Samson T. Jacob, Ohio State 
University, US) contain the mouse MBD2 or MBD3 cDNAs in the pcDNA3.1 vector 
(Invitrogen) (Ghoshal et al., 2004). The MBD1 expression vector contains the full 
length cDNA for mouse MBD1 (Acc. No. NM_013594; F; tac ctc tag aat ggc tga gga 
ctg gct gga ctg, R; ttt cta gaa aca att tgc aaa gaa ttt tca gg) inserted in the pRK7 
expression vector. CaMKII expression vectors contained either full-length CaMKII 
(1-317) or CaMKII (1-290), which is constitutive active due to the absence of the 
calmodulin-binding domain (graciously gifted by Anthony R Means Dept. of 
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Pharmacology and Cancer Biology, Duke University Medical Center, P. O. Box 3813 
Durham, NC). The constitutive active CaMKII (T286D) contains a replacement of 
Thr 286, which locates in the autoinhibitory domain by Asp (graciously gifted by 
Gina Turrigiano, Department of Biology, Volen National Center for Complex 
Systems, Brandeis University, Waltham, MA 02454, USA). 
2.2.4.4 Recombinant protein construct 
The plasmid GST-MeCP2 (pGex2tk-MeCP2) was used to produce recombinant 
MeCP2 protein for EMSA experiment. For prokaryotic expression, the MeCP2-alpha 
cDNA was PCR amplified (F; aag gga tcc gta gct ggg atg tta gg, R; tct gat atc ctc agt 
ggt gga gga gga g) and inserted into the BamHI and SmaI sites of pGex2tk 
(Pharmacia). All constructs used in this study were entirely sequence verified. 
2.2.4.5 Site-directed mutagenesis 
In order to test the specificity of phospho-MeCP2 antibodies, the phospho residue Ser 
97 and Ser438 were replaced in MeCP2 by alanine using site-directed mutagenesis. 
Site-directed mutagesis was performed using a two sep PCR method. The pRK-Flag-
MeCP2 vector was used as the parental vector. The oligonucleotides for this 
mutagenesis are listed below: 
S97A Sense: 5’-GAA GCC TCG GCT CGA CCC AAA CAG CGG-3’ 
S97A Antisense: 5’-CCG CTG TTT GGG TCG AGC CGA GGC TTC-3 
S438A Sense: 5’-CCC GAG GAG GCC GAC TGG AAA GCG ATG GC-3’ 
S438A Antisense: 5’-GCC ATC GCT TTC CAG TCG GCC TCC T G GG-3’ 
Briefly, the first PCR contained 50 ng vector DNA, 125 ng of oligonuleotide 
(sense or antisense), 1 µl of dNTP (10mM), 10x Pfu reaction buffer, 1 µl Turbo Pfu 
polymerase (Fermentas) and filled up to 50 µl with distilled water. After initial 
denaturation for 3 minutes at 95 °C, 10 amplification cycles (95 °C, 30 sec; 60 °C , 60 
sec; 68 °C, 10 mins) were carried out. 
In the second PCR reaction, 25 µl of sense and 25 µl of antisense PCR product 
were taken from the first PCR. Following addition of 0.5 µl of Pfu polymerase, PCR 
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reactions were performed as below. After the first initial denaturation of 3 minutes at 
95 °C, 20 amplification cycles (95 °C, 30 sec; 56 °C, 60 sec; 68 °C, 10 mins) were 
performed. 2 µl of PCR product were taken to check amplification progress by gel 
electrophoresis. Then PCR products were purified by spin column (Macherey-Nagel). 
50 µl of water was added to elute the PCR product. In order to remove the parental 
vector, DpnI digestion was performed which contained 45 µl of eluate, 5 µl of 10x 
buffer and 1 µl of DpnI (10U/µl). After incubating the sample at 37 °C for 90 
minutes, the sample was heat inactivated at 65 °C for 10 minutes, then purified by 
phenol/chloroform and ethanol precipitation. Finally, DNA was resuspended in 10 µl 
of water. 2 µl of vector DNA was transformed in electrical competent bacteria. 
Sequencing was carried out to verify the mutation. 
2.2.4.6 In vitro  methylation  
The CpG methyltransferase, M.SssI (New England Biolabs), can methylate all 
cytosine residues (C5) within the double-stranded dinucleotide recognitio  sequence 
5'...CG...3'. The protocol was as follows: in the first step, 32 mM SAM stock was 
freshly diluted to 1600 µM. Then reaction was set up in a volume of 20 µl by adding 
the following reagents: 11 µl of nuclease free water, 2 µl of 10×NEBuffer, 2 µl of 
diluted SAM from previous step, 4 µg of plasmid DNA and 1 µl of SssI methylase (4 
U/µl). The reaction was incubated at 37 °C for 1 hour. Then the reaction was stopped 
by heating at 65 °C for 20 minutes. After phenol/chloroform purification and ethanol 
precipitation, the vector was ready to use. 
2.2.4.7 Site-directed DNA methylation 
Site-directed DNA methylation was performed to methylate specific CpG 
dinucleotides (CpG 6−8) in a Pomc promoter vector (CpGL-Pomc). 5 µg of CpGL-
Pomc vector was double digested with BglII and HindIII whereby only CpG 6−8 
remained in the backbone vector. To prevent recircula ization of the cloning vector, 
Calf Intestinal Alkaline Phosphatase (CIAP), which removes 5´ phosphates from the 
vector DNA, was added to the digestion system. The vector DNA was first purified on 
a PCR cleanup column; then in vitro methylation was carried out as mentioned above. 
In the control, all steps remained the same with one exception: in the in vitro 
methylation step, 1 µl of water was added instead of 1U of Methylase SssI. In 
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parallel, 5 µg POMC PCR products were also double dig sted with BglII and HindIII. 
After PCR product purification, the PCR product was ligated to the backbone vector 
which contained methylated CpG 6−8. After overnight ligation, the product was 
subjected to phenol/chloroform purification and ethanol precipitation. To verify the 
methylation status of the plasmid vector, bisulfite sequencing was performed. The 
final patch DNA methylation product was enough for 3 t ansfections (3 wells) in a 12-
well plate.  
2.2.4.8 Plasmid preparations 
I) Small-scale preparations 
In order to screen positive recombinants, plasmid DNA was extracted from E.coli. 
Colonies were picked from an agar plate and incubated in 1.5 ml growth medium 
supplemented with appropriate antibiotics (Zeocin, 25 µg/ml; Ampicilin 100-200 
µg/ml). The cultures were incubated 6−8 hours or overnight at 37 °C in a shaker 
(rotation 200 rpm). 1.5 ml of each overnight culture was transferred in a 1.5 ml 
reaction tube and centrifuged (10 min, 9000 g, RT) to pellet the bacteria. The cell 
pellet was resuspended in 200 µl TEG (25 mM Tris pH 8.0, 10 mM EDTA, 100 µg/ml 
RNase A, and 1% glucose) on a shaking platform or vortexer, lysed by adding 200 µl 
alkaline SDS (200 mM NaOH, 1% (w/v) SDS) and mixed by inverting the tube for 
6−8 times. After incubation at RT for 5 minutes, 200 µl of 3M KAc was added. The 
tube was inverted again for 6−8 times and then kept on ice for 10 minutes before  
centrifugation (10 min, 13,000g, RT). The plasmid DNA in the supernatant was 
transferred into a new 1.5 ml tube and 500 µl of isopropanol was added. The tube was 
incubated on ice for 30 minutes and then centrifuged (20 min, 13,000 g, 4 °C) to 
pellet the plasmid DNA. The pellet was washed with 70% ethanol and centrifuged (5 
min, 13,000 g, 4 °C). The supernatant was carefully aspirated; the pellet was air-dried 
and redissolved in 25 µl TE (10 mM Tris, 1 mM EDTA). The plasmid DNA can be 
used immediately or stored in a -20 °C freezer. 
II) Large-scale preparations  
To obtain 100 µg of plasmid DNA or more, maxiprep was performed. A single clone 
was picked from the agar plate, then incubated overnight at 37 °C with vigorous 
shaking in 2 ml of SOB (tryptone 20 µg/ml, yeast extract 5 µg/ml, NaCl 10 mM, KCl 
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2.5 mM) medium with appropriate antibiotics. On thenext day, 2 ml of the overnight 
culture was added to a 500 ml flask containing 40 ml of TBA (tryptone, 12 µg/ml; 
yeast extract, 24 µg/ml; glycerol, 0.4%) and 10 ml of TBB (KH2PO4, 0.17 M; 
K2HPO4, 0.72 M) with appropriate antibiotics. The culture was incubated overnight at 
37 °C with shaking (200 rpm). The plasmids were purified using a Macherey-Nagel 
plasmid maxiprep kit. 
2.2.5 Cell culture and transfection experiments 
2.2.5.1 Cell cultures  
LLC-PK1 cells are an epithelial cell line (ATCC No. CL-101) originally derived from 
porcine (pig) kidneys. The cells show a fibroblastic-like morphology and were grown 
in Dulbecco’s Modified Eagle Medium (DMEM) supplement d with 10% fetal calf 
serum (FCS). In this study, LLC-PK1 cells were used for transfection of pRK-MeCP2 
vectors by electroporation to validate MeCP2 antibod es. 
AtT-20/D16v-F2 (mouse pituitary epithelial-like tumor cell line) cells (ATCC 
No. CRL-1795) are corticotrope and are derived from a neuroendocrine tumor, which 
endogenously expresses two distinct somatostatin receptor subtypes (SRIF). They are 
used in transfection studies to investigate endocrine and exocrine secretory pathways, 
in particular ACTH (adrenocorticotropic hormone) and beta-endorphin. The F2 
subclone of AtT-20 (see ATCC CCK-89) was developed by B. Gumbiner. This clone 
had been used successfully by Moore et al. (Moore et al., 1983a, b) for several DNA 
mediated transfection studies relating to endocrine a d exocrine secretory pathways. 
In this study, AtT20 cells were used for the investigation of Pomc gene activation by 
various treatments and stimuli. AtT20 cells were grown in DMEM supplemented with 
10% FCS. 
Neuro2A is a mouse neuroblastoma cell line (ATCC No. CCL-131) established 
by R.J. Klebe and F.H. Ruddle in 1969 (Klebe, 1969) from a spontaneous tumor of an 
albino mouse strain and are neuronal in morphology. In this study, we extracted DNA 
from Neuro2A cells and performed bisulfite sequencing to check Pomc DNA 
methylation status. Neuro2A cells were grown in DME supplemented with 10% 
FCS. 
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AtT-20 (V1bR) cells are corticotrope cells with the mouse vasopressin V1b 
receptor stably expressed. These cells were kindly gift from Dr. Eric Clauser 
(INSERM U970, Paris, France). They were used in trasfection studies to investigate 
Pomc luciferase activity after AVP treatment as well as in ICC experiments to 
examine MeCP2 phosphorylation after AVP treatment. AtT20 (V1bR) cells were 
grown in 50% MF12/50% DMEM Glutamax supplemented with 10% FCS, 10% Nu 
serum (BD biosciences), geneticin (0.5 mg/ml) and 1% Penicillin/streptomycin 
(Biochrom) as antibiotic. 
2.2.5.2 Primary pituitary cell culture  
For mouse primary pituitary cell culture, tissues were removed from adult male mice 
(~6 weeks old) and stored in HD-buffer (Hepes 25 mM, NaCl 137 mM, KCl 5 mM, 
Na2HPO4 0.7 mM, glucose 10 mM, Partricin (A2812, Biochrom) 25 mg/l, and 
Penicillin/Streptomycin (A2213, Biochrom) 105 units/l). After washing several times 
with HD-buffer, pituitaries were chopped up into small pieces by scissors. The HD-
buffer was removed, then 5 ml of collagenase (Worthington Biochem) solution was 
added to the cells to dissociate the extracelluar mat ix. After incubation of the cells in 
a 37 °C incubator about 2 hours, 35 ml of cell culture medium (50 ml FCS (Gibco), 5 
ml glutamine (Biochrom), 5 ml Pen/Strep (Biochrom), 5 ml Partricin (Biochrom), 
MEM-vitamins (Biochrom), 2.5 mg insulin (Sigma), 2.5 mg transferrin (Sigma), 30 
pm T3 (Sigma), 10 µg sodium selenite (Sigma) in 500ml DMEM medium (Gibco)) 
was added to stop the reaction. Living cells were counted by acridine orange/ethidium 
bromide staining and pituitary cells were seeded into 12-well culture plates at a 
concentration of 100.000 cells/ml. Two days later, growth medium was replaced with 
fresh culture medium and cells treated either with KCl (55 mM) or AVP (100 nM). 
The calmodulin kinase II inhibitor (1 µM, EMD Chemicals, Gibbstown, USA) or the 
AVP V1b receptor antagonist--SSR149415 (1 µM, Axon1114, Axon medchem) were 
added to the medium 30 minutes before stimulation. 
2.2.5.3 Transfection 
LLC-PK1 cells were seeded one day before electroporation. They were harvested by 
trypsinisation and resuspended in 1x Electroporation buffer (1x EP buffer) (50 mM 
K2HPO4, 20 mM CH3KO2, 20 mM KOH) to adjust to a concentration of 2 x 10
7 
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cells/ml. 1 x 106 cells in 50 µl of this was added to a 100 µl mixture containing 200 ng 
of pRK-MeCP2 vector, 2 µg CaMKII vector, 4 µl MgSO4, 20 µl 5 x EP buffer, 2 µg 
PAM carrier DNA, and water. This was incubated at room temperature for 10 
minutes, placed in a cuvette and then electroporated using a BTX 600 electroporator 
(290 V, 500 µF, 360 Ω). After pulse delivery, the cells were immediately transferred 
to 6-well culture dishes containing 2 ml of DMEM+10% FCS and incubated 
overnight at 37 °C with 5% CO2.  
AtT20 cells were transfected using lipofectamine reagent. One day before 
transfection, 1 x 105 AtT20 cells were seeded in 1 ml DMEM+10% FCS onto 12-well 
tissue culture dishes and grown until 50−8 % confluence. The medium was removed 
prior to transfection and the cells were rinsed with 200 µl of Opti-MEM without FCS. 
For each well, 6 µl of lipofectamine reagent was mixed with 2 µg of pCpGL-Pomc-
luciferase vector and 0.5 µg pRK7-β-gal which was mixed in 100 µl of Opti-MEM 
medium without serum. The plasmid Opti-MEM mixture was added to Lipofectamine 
Opti-MEM mixture dropwise, then the mixtures was incubated for 45 minutes at room 
temperature to allow complexes to form. These complexes were added to the rinsed 
cells and incubated for 6 hours. After this 400 µl of DMEM+20%FCS was added, and 
cells incubated overnight at 37 °C. 24 hours after transfection, luciferase activity was 
measured. 
2.2.5.4 Luciferase assays 
To measure promoter activity, cells were washed twice with PBS and then thoroughly 
lysed in 100 µl lysis buffer (75 mM Tris-HCl, 10 mM MgCl2, 1% Triton X-100, 2 
mM ATP, 1 mM DTT). 80 µl of aliquots were measured in a LKB luminometer for 20 
seconds. As an internal control of transfection efficiency, the luciferase readings were 
nomalized on β-galactosidase activity from a cotransfected expression vector (pRK7-
β-gal) (Hoffmann et al., 2003). The β-gal activity in the extracts was measured as 
described previously (Spengler et al., 1993).  
2.2.6 Protein preparations 
2.2.6.1 Recombinant proteins 
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Recombinant GST-MeCP2 fusion proteins were used for EMSA experiment. 
Following transformation of pGEX-2TK-MeCP2 into DH5α bacteria, single colonies 
were grown at 37 °C in 50 ml 2YT (0.16% tryptone, 0.1% yeast extract, 0.1% NaCl) 
overnight, to which a futher 450ml 2YT was added angrown for 3 hours until an OD 
600 of 0.5−1.0 was reached. After that, they were incubated at a final concentration of 
1 mM IPTG for another 2 hours at 30 °C. The GST-MeCP2 protein was purified 
using glutathione-sepharose beads (Hoffmann et al., 2003). Eluted GST-MeCP2 was 
shown to be of at least 95% purity as judged by Coomasie blue staining. The 
concentration of GST-MeCP2 was determined using Bradfo d assays and aliquots 
were stored at -80 °C until usage.  
2.2.6.2 Protein concentration and purity 
Bradford assays were applied to determine the concentration of all proteins used in 
this study. The assay is based on the observation that the absorbance maximum for an 
acidic solution of Coomasie Brilliant Blue G-250 shifts from 465 nm to 595 nm when 
binding of the dye to proteins occurs. Both hydrophobic and ionic interactions 
stabilize the anionic form of the dye, causing a visible colour change. The 
concentrated assay buffer was first diluted 1:5 and standards were prepared containing 
a range of 20 to 200 µg protein (BSA). The samples were diluted (3 µl in 200 µl 
water) to an estimated concentration of 20 to 200 µg/ml. 800 µl Bradford reagent was 
added to each sample and protein standards, and the absorbance was measured at 590 
nm. Protein concentrations of samples were deduced from the standard curve. 
Coomassie blue staining was then further used to assess the purity and integrity of 
recombinant protein preparations. Protein samples wre loaded onto an SDS-PAGE 
gel with a size marker and fractionated at 150 V. The gel was then soaked in 0.2% 
Coomassie blue for 1 h and destained in 40% methanol, 50% acetic acid solution over 
night. The gel was then blotted on to paper and dried. All proteins used in the study 
were of at least 95% purity. 
2.2.6.3 Electrophoretic mobility shift assay (EMSA) 
EMSA was used to determine the affinity of a protein for a particular DNA sequence. 
In these EMSA experiments, recombinant GST-MeCP2 protein was incubated with 
20,000 cpm of double-stranded end labelled oligonucleotides. Sense and antisense 
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oligonucleotides contained the CpG dinucleotide neighboured by an AT rich sequence 
and an overhanging GTG for end labelling. The oligonucleotides used for EMSA 
experiment are listed in Figure 6. In order to show the importance of the methylated 
CpG dinucleotide and the adjacent AT rich sequence to MeCP2 binding, a series of 
mutated oligonuleotides were designed. They either contained a mutated CpG 
dinucleotide to abolish DNA methylation or carried mutation(s) in the AT rich region. 
An oligonucleotide encoding a previously reported MeCP2 binding site was used as 
positive control. This binding site was identified previously as high affinity MeCP2 
binding site (Klose et al., 2005). 
 
Figure 6. Oligonucleotides derived from the Pomc promoter region used in the EMSA 
experiments. CpG dinucleotides are shadowed in gray and AT runs in yellow. The location and 
sequence of the oligonucleotides used for the EMSA experiments are underlined. The sequence 
marked in cyan indicates Pomc exon1.  
In the EMSA experiment, oligonucleotides were annealed in a reaction volume 
of 40 µl containing 1 µg/µl of each of the sense and antisense oligonucleotids and 4 
µl of annealing buffer (1.5 M NaCl, 100 mM Tris-HCl pH 7.9). The oligonucleotides 
were heated at 85 °C for 10 minutes to ensure DNA double-strand separation, and 
then slowly cooled down to room temperature by switching off the heat-block to 
allow for efficient annealing of the sense to the antisense strands. The double-strand 
oligonucleotides were in vitro methylated (see in vitro methylation) by CpG 
methyltransferase (M.SssI, NEB). Unmethylated and methylated oligonucleotides 
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were diluted to 50 ng/ml and used in parallel in the labelling reaction. For the 
labelling reaction, the mastermix was prepared as follow: 1.5 µl of oligo mix (50 
ng/µl), 2.0 µl  of 10×Klenow buffer, 3.0 µl  32P-dCTP, 4.0 µl  of dATG, 1 µl of 
Klenow enzyme and water to 20 µl. This mastermix was incubated at room 
temperature for 45 minutes and 4 µl of dCTP (5 mM) was added. The mixture was 
incubated again for 5 minutes at room temperature and the oligonucleotides were 
purified by biospin column. 1 µl of the mixture was taken for counting. The labelled 
oligonucleotides were dissolved to 20.000 cpm/µl by distilled water. A working stock 
of 20.000 cpm/µl labelled oligonucleotide was used for all EMSA exp riments. The 
binding reaction was then performed using 5 µg of GST-MeCP2 protein in a volume 
of 20 µl reaction buffer (10 mM Tris-HCl pH 8, 3 mM MgCl2, 66 mM KCl, 100 
µg/ml BSA, 12% glycerol, 1 µg/µl of dI/dC, 1 mM DTT). This was incubated on ice 
for 5 minutes and then 20,000 cpm of labelled oligonucleotide was added and the 
whole reaction was incubated for a further 25 minutes at room temperature. 3 µl of 
6×DNA loading dye was added and the samples were loaded on a 5% polyacrylamide 
gel (non denaturating). The gel, which was pre-run for 30 minutes (4°C; 150V; 0.5x 
TBE) was run with the samples at 100V for around 1 hour at 4°C. Hereafter, the gel 
was dried and subjected to autoradiography overnight. 
2.2.6.4 Western blots 
Transfected or non-transfected AtT20 and LLC-PK1 cells were used for western 
blots. Cells were seeded in 10 cm or 6-well plates 24 hours before harvesting. The 
cells were first washed twice with cold 1−5 ml 1x PBS. Then cells were scrapped in 
0.2 to 0.5 ml TE buffer with protease inhibitor cocktail (1/100) and phosphatase 
inhibitor cocktail (1/100). The cells were disrupted by ultrasonification for 3 minutes 
(30-second interval) in an ice bath.  An aliquot of 3 µl was kept at this step for 
measuring protein concentration by Bradford. The remaining cell lysates were added 
4x Laemmli buffer (200 mM Tris-HCl pH 6.8, 8% SDS, 40% glycerol, 0.4% 
Bromophenol blue, 0.1% β-mercaptoethanol) according to the volume. The cells were 
heated to 95 °C in a heatblock for 5 minutes to denature proteins. All the samples 
were kept in the -20 °C freezer ready to use. An 8% SDS-PAGE gel was prepared. 50 
µg of whole cell extract (WCE) was loaded to each well. The SDS-PAGE gel was run 
at 120 V in the cold room with a water flow for cooling. When the 35 kD pre-stained 
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maker reached the bottom of the gel, the proteins were transferred to a nitrocellulose 
membrane in a transfer chamber at 50 V for 2 hours in the cold room. The membrane 
was briefly stained with Ponceau red to check if the proteins had transferred from the 
gel to the membrane. Unspecific binding of the antibod es to the membrane was 
blocked by placing the membrane in blocking buffer (10 mM Tris, 0.5 M NaCl, 0.1% 
Tween, 5% BSA, pH 7.6) which was incubated on a shaker t room temperature for 1 
hour. The blocking solution was poured off and the m mbranes incubated with the 
primary antibody in a shaker over night at 4 °C. Membranes were then washed 5 
minutes three times with TBST (0.1 % Tween-20) to remove unbound antibody and 
then incubated for 1 hour at RT with the second conjugated antibody. The membranes 
were washed as before. A 1:1 mixture of the chemiluinescent reagent was prepared 
and added to the membrane for 2 minutes. Then the membrane was dried slightly and 
wrapped in saran wrap. The first film was exposed for 30 second to check signal 
appearance and then exposure time was adjusted to the strength of the signals. 
2.2.6.5 Protein de-phosphorylation 
De-phosphorylation was performed to demonstrate the specificity of the phospho-438 
MeCP2 antibody. For an antibody that only binds its phospho-site when the protein is 
denatured, treating the membrane with phosphatase po t-transfer is preferable to treat 
the non-denatured lysate. After SDS-PAGE gel electrophoresis, the proteins were 
transferred to a nitrocellulose membrane which had been blocked by pretreatment with 
5% BSA in TBS with 0.1% Triton X-100 for one hour at room temperature. The 
membrane was cut to obtain a slot containing at least one sample duplicated in the 
other piece. The two pieces of membrane were placed in separate containers with 3−5 
ml CIP buffer inside. The CIP enzyme was added to the container with the piece to be 
de-phosphorylated. After incubation at 37°C for one hour, the samples were subjected 
to the standard western blot procedure. 
2.2.6.6 Immunohistochemistry 
Pituitary slides, primary pituitary or AtT20 cells were fixed with 4% 
paraformaldehyde in phosphate-buffered saline (PBS) for 5 minutes. Coverslips were 
washed with PBS for 5 minutes, and then blocked for 2 hours with blocking solution 
(50 mg/ml BSA, 50 mg/ml goat serum, 0.5% Triton X-100, 50 mM Tris-HCl, 50 mM 
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NaCl and pH7.4). Coverslips were incubated with the following primary antibodies 
diluted in blocking solution overnight in a humidifying chamber at 4°C: total MeCP2 
(1:400); pS438-MeCP2 (1:400), CaMKII (1:500), pCaMKII (1:500) and ACTH 
(1:400). Coverslips were washed three times with PBS for 10 minutes. Secondary 
antibodies were diluted in blocking solution, and incubations were performed at room 
temperature for 2 hours. Coverslips were washed with PBS three times for 10 minutes 
then DAPI was added at 1:6000 in PBS for 5 minutes. After washing with PBS three 
times for 10 minutes, the coverslips were mounted.  
2.2.7 Statistical analysis and computer software 
CpG island analyses was performed using the online program CpG Plot 
(http://www.ebi.ac.uk/Tools/emboss/cpgplot/) and EMBOSS (Rice et al., 2000). The 
heatmap was generated using the online free software Heatmap Builder. Primers were 
designed according to the general guidelines by the software Oligo 6. For pituitary 
corticotrope cell counting, the total cell number was counted automatically by the 
software of Cell C; and the corticotrope cell number was counted manually using the 
software Image J. Graphs were drawn by the software Sigma Plot and Microsoft 
Excel. All statistical analyses were performed by Microsoft Excel. All figures were 
designed through CoralDraw software version 10 (Corel Corporation, Ottawa).
RESULTS 
                                                                                                                                                    48                                                                                                                                                             
3 Results 
 
3.1 Biometric data 
3.1.1 Experimental design 
 
We carried out maternal separation (MS) to model early life stress. This maternal 
separation model is based on the fact that in the wild field, the dam will leave the nest 
ranging from 15 minutes to 3 hours for foraging. The higher rank of the mother, the 
less time she will spend. During her absence, it isvery stressful for the litters. It is 
also suggested that the first 10 days of life is a critical time window for mouse 
development. This traumatic event early in life can lead to severe consequences at 
later stage when they reach adulthood.   
 
Figure 7.  Maternal separation model and experimental design. 
The procedure of maternal separation is as following: the new born mice were 
separated 3 hours daily from their mother from postnatal day 1 to day 10. After P10, 
all the mice lived with their mother. In this experiment, 4 time-points were 
investigated: P10, 6 weeks, 3 months and 1 year. Both male and female mice were 
used for biometric, neuroendocrine, gene expression and DNA methylation analysis. 
Male mice were used for the behavioral tests and the investigation of molecular 
mechanisms. 
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3.1.2 Behavioral analysis of adult offspring  
To assess long-term alterations in behavior due to arly life stress exposure, we 
performed a series of behavioral tests. Only male mice were used in the experiments, 
and these data had been published previously (Murgatroyd et al., 2009). In summary, 
early life stress (ELS) produced long-lasting behavioral changes for the following 
criteria. First, adult ELS mice (6-week-old) showed memory deficits in an inhibitory 
avoidance task. Second, ELS mice had increased immobility in the force swim test. In 
contrast, anxiety-like behavior was unaffected by early life stress in the elevated plus-
maze, novelty-induced hypophagia and light-dark avoidance test. 
3.1.3 Biometric data 
3.1.3.1 Body weight 
 There were no significant body weight differences (p > 0.05, t-test) between ELS and 
control mice through all timepoints (6 weeks, 3 months and 1 year) in both sexes 
(Figure 8). These data supported the idea that ELS is a psychological stressor rather 
than a physical intervention such as sickness or famine. 
 
Figure 8. Mouse body weight after early life stress.  There is no difference in body weight 
between control and early life stress (ELS) mice at all ages in both sxes. Data are mean ± S.E.M 
(n=8−10/group). 
 
3.1.3.2 Thymus weight 
 
Thymus glands of control and ELS mice were dissected and weighed at each 
timepoint. The relative weight (mg/100g BW) of the thymus in ELS mice was 
significantly lower (p < 0.05, t-test) than controls (Figure 9), which is in according 
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with the fact that ELS mice had higher levels of corti sterone (Figure 11) in the 
plasma. 
 
Figure 9. Reduced thymus weight after early life stress. As compared with controls, early life 
stress mice showed involution of thymus weight at all ages in both genders, indicative of higher 
levels of corticosterone (Cort) in the blood. Data re mean ± S.E.M (n=8-10/group). *p<0.05 (t-
test).      
 
 
3.1.3.3 Adrenal weight 
 
 Adrenal glands from male and female mice were alsodi sected and weighed. The 
relative weight of adrenal gland (mg/100g BW) was significantly higher in the ELS 
group than the controls (p < 0.05, t-test) in both genders (Figure 10). Furthermore, 
adrenals weighed significantly less in males than females irrespective of rearing 
condition. Previous study demonstrated that adrenal gland growth and function is 
under the control of pituitary derived ACTH. The hypertrophy of the adrenals in the 
ELS group predicted a hyper-secretion of ACTH compared with control mice.  
 
Figure 10. Increased adrenal weight after early life stress. As compared with controls, early 
life stress mice showed larger adrenals at all ages in both genders, predicting higher level of 
adrenalcorticoal (ACTH) in the blood. Data are mean ± S.E.M (n=8−10/group). *p < 0.05 (t-test).   
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3.1.4 Plasma corticosterone (Cort) levels 
 Basal evening and morning plasma corticosterone lev ls were measured. In both 
conditions, plasma corticosterone concentrations were higher in ELS mice compared 
with controls in both genders. Female animals had a higher overall concentration of 
corticosterone than males (Figure 11). 
 
Figure 11. Increased serum levels of corticosterone (Cort) after early life stress. ELS mice at 
6 week, 3 month and 1 year time points presented with increased serum corticosterone levels 
under peak and basal conditions. Data are mean ± S.E.M (n=8−10/group). *p < 0.05 (t-test). 
 
3.1.5 Pomc mRNA expression 
 
Basal Pomc mRNA expression in mouse pituitary was measured by quantitive real 
time PCR (q-PCR). As shown in Figure 12, ELS mice produced a significant increase 
of Pomc mRNA level in the pituitary compared with controls from 10 days old mice 
up to 1 year. To facilitate comparation of relative mRNA level between different 
timepoints and between genders, cDNA from mouse pituitary AtT20 cells was used as 
the general standard throughout the experiments. As shown in Figure 12, basal Pomc 
mRNA expression slightly increased with age irrespectiv  of gender. Furthermore, 
when compared the Pomc mRNA levels between genders, baseline Pomc mRNA 
expression in females was significantly higher than in males. 
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Figure 12. Pomc mRNA level after early life stress. Pomc mRNA was significantly higher in 
the pituitaries of ELS mice at all time points both in male (left) and female (right) animals as 
determined by qPCR analysis. Data are mean ± S.E.M (n = 8−10/group). *p < 0.05 (t-test). 
Pomc mRNA is expressed both in the anterior lobe and intermediate lobe of the 
pituitary, but processed differently by cell type specific enzyme usage. To address the 
question whether Pomc mRNA expression could be altered due to early life str ss 
exposure in the intermediate lobe, we dissected the intermediate lobe (6-week-old) 
from the anterior pituitary and tested the Pomc mRNA levels from anterior lobe and 
intermediate lobe separately by real-time PCR. The results showed that early life 
stress resulted in upregulation of Pomc mRNA in the anterior pituitary. On the 
contrary, early life stress did not influence Pomc mRNA in the intermediate lobe 
(Figure 13). 
 
Figure 13. Early life stress produced increased levl of Pomc mRNA in the anterior 
pituitary. (A) Representative bright-field autoradiographs of pituitary sections (6-week-old 
males) hybridized with a 35S-labeled oligonucleotide probe complementary to Pomc mRNA from 
a Ctrl (upper) or ELS (lower) mouse. AP, anterior pituitary; IL, intermediate lobe; PP, posterior 
pituitary. Scale bar, 500 µm. In situ hybridization showed that Pomc expression is much higher in 
ELS mice. (B) Pomc mRNA expression was significantly higher in ELS than controls in the 
mouse anterior pituitary (6-week-old males). (C) ELS did not influence Pomc mRNA expression 
in the intermediate pituitary. Data are mean ± S.E.M (n = 8−10/group). *p < 0.05 (t-test). 
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3.1.6 Serum ACTH level and AVP-CRH challenge test 
 
ACTH, which is cleavaged enzymatically from POMC in the antior pituitary, was also 
measured in the blood of 6-week-old mice. Consistent with the Pomc expression 
patterns in the pituitary, blood ACTH levels were also higher in ELS mice than 
controls in both genders. Early life stress also increased sensitivity of the pituitary-
adrenal axis to the hypothalamic secretagogues CRH and AVP in both genders. When 
the mice were treated with AVP and CRH peptides, the early life stress (ELS) group 
mice displayed much higher responsiveness compared with control mice (Figure 14).  
 
Figure 14. Early life stress increased sensitivity of the pituitary-adrenal axis to CRH and 
AVP in both genders. Under basal conditions, blood ACTH levels were higher in ELS mice (6-
week-old) in both genders. ELS mice displayed much higher responsiveness compared with 
control mice after AVP and CRH application. Data are mean ± S.E.M (n = 8−10/group). *p < 0.05 
(t-test). 
 
3.2 Pomc DNA methylation status 
3.2.1 DNA methylation at the Pomc gene locus in naïve mice 
Here, we used the in-bred mouse strain C57BL/6N. All mice were housed under the 
same condition. The only difference between control mice and ELS mice came from 
the maternal separation procedure.  External stimulations can change the phenotypes 
later in life; we hypothesized that epigenetic processes could be responsible for this 
fact. DNA methylation is a stable epigenetic mark at CpG dinucleotides, which often 
couples to lasting changes in gene transcription. Methylation of cytosine residues 
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within CpG dinucleotides can result in gene silencing; such CpGs are conspicuously 
under-represented in mammalian genomes and typically luster with GC-rich regions 
called CpG islands (CGI). In the case of Pomc gene, computational analysis 
(CpGPlot, EMBOSS) and previous literature (Gardiner-Ga den and Frommer, 1994) 
revealed 2 CpG islands within mouse Pomc gene locus: CpG island 1 (CGI 1) which 
surrounds the Pomc transcription start site and CpG island 2 (CGI 2) which lies 
approximately 5 kb downstream, encompassing the third exon of Pomc gene.  
 
Figure 15. DNA methylation status at the Pomc gene locus. (A). Schematic diagram of the 
mouse Pomc gene. Exons are indicated by open (numbered) boxes and CGIs by numbered bars, 
and the distribution of CpG residues are listed according to their position. (B). Sequence analysis 
of bisulfite-converted DNA isolated from the pituitaries of naive C57/BL6 mice (3-month-old) 
showed sparse methylation in the core promoter (CGI 1) and the coding region (CGI2). In 
contrast, high levels of CpG methylation were found at the far distal promoter region of the Pomc 
gene. Comparing the DNA methylation level between male and female revealed that males show 
higher level of DNA methylation than females. Data re mean ± S.E.M (n=8-10/group). *p < 0.05 
(t-test). 
To investigate the DNA methylation status at the Pomc gene locus, sodium 
bisulfite conversion was performed with genomic DNA isolated from pituitaries. Four 
pairs of primers were designed to cover the entire CGI 1 and part of CGI 2 (Figure 
15). Sodium bisulfite treatment of DNA samples converts non-methylated cytosines 
(C) to uracils (U), which are then replaced by thymidine (T) in the subsequent PCR 
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reactions. Methylated cytosines (mC) are unaffected by sodium bisulfite reaction and 
the differences in methylation status are thus apparent and easily detected on sequence 
reads. 
The pituitary was dissected away from the brain, and genomic DNA was isolated 
and treated with sodium bisulfite. Sequence analysis of bisulfite-converted DNA 
isolated from the pituitaries of naive C57BL/6N mice (3 months old) showed sparse 
methylation in the core promoter CGI 1 and the coding region CGI 2. In contrast, we 
found high levels of CpG methylation clustered at the far distal promoter region of 
Pomc encompassing CpG1 to CpG16 (Figure 15); this region has been shown in the 
previous literature to play a critical role in Pomc gene regulation. When DNA 
methylation was compared between genders, male mice showed higher levels of DNA 
methylation than females at the Pomc distal promoter region (Figure 15 and Figure 
16). 
3.2.2 Early life stress dependent DNA methylation  
As shown in the previous chapter (Figure 12), ELS induced higher levels of Pomc 
mRNA in the pituitary; therefore we wondered whether DNA methylation might play 
a role in regulating Pomc gene expression during early life adverse events. Bisufite 
sequencing was performed between ELS and control mice aged 10 days, 6 weeks, 3 
months and 1 year in both genders. The results showed that no differential DNA 
methylation was observed at all time points either in the coding region, which is 
confined as CGI 2 (CpG 30-45), or in the core promoter region (CpG 17-28)  as well 
as in the 5’ UTR (CpG 1-5). By contrast, ELS induced hypomethylation at the Pomc 
distal promoter region ranging from CpG 6 to CpG 16. To facilitate the comparison of 
DNA methylation through age and between genders, heatmaps were deduced to 
illustrate the DNA methylation status. DNA methylation levels were transformed into 
graded-color, ranging from 0% of methylation (yellow) to 100% of methylation (red). 
In these heatmaps, the x-axis represents a single CpG residue from CpG 6 to CpG 16 
at the Pomc distal promoter region, and every single row stands for a single mouse 
subjected to bisulfite mapping.  
The heatmap showed that early life stress produced a significant decline of DNA 
methylation through the Pomc distal promoter in ELS mice aged 10 days, 6-week, 3 
months, and 1 year in both genders. Importantly, this region has been shown to be a 
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critical area both for pituitary specific Pomc gene expression and Pomc activation 
from upstream secretagogues, such as CRH and AVP. Overall, these findings revealed 
that ELS triggered a heterogeneous response in CpG hy omethylation and indicated a 
functional role for the detected changes. 
In addition, examination of the methylation status of all CpGs found within the 
Pomc promoter of naïve mice revealed a general decline in methylation in 1-year aged 
mice compared with 6-week aged animals, with 30% of all CpG residues showing a 
significant decline (Figure 16B). Correspondingly, increased levels of Pomc mRNA 
expression was observed in 1 year old naïve mice compared with 6 weeks animals 
(Figure 12), indicating that age-associated DNA hypomethylation might contribute to 
the elevated Pomc mRNA expression. However, in contrast to males, femal s did not 
show any age-associated drift in DNA methylation (Figure 16D).  
Figure 16. Early life stress induced hypomethylation at the Pomc distal promoter region. (A 
and C). Comparison of the DNA methylation status from ELS and control mice aged 10 days, 6 
weeks, 3 months and 1 year, the results showed hypomethylation of multiple CpG residues 
throughout the far distal promoter region in ELS mice both in males (A) and females (C). (B). 
Analysis of overall methylation of the distal promoter revealed age-related substantial reductions 
in methylation. (D) Overall DNA methylation of female control mice did not show any age-
associated drift. *p < 0.05 (t-test) 
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3.2.3 Pomc DNA methylation in different tissues 
The DNA methylation status at the Pomc distal promoter ranging from CpG 6 to CpG 
16 from different tissues was studied by bisulfite mapping. As shown in Figure 17, the 
Pomc gene showed a tissue-specific DNA methylation pattern. In normal non-
expressing tissues, such as adrenal, kidney, spleen, thymus, hippocampus and the non-
expressing cell line Neuro2A (data not shown), the Pomc distal promoter was hyper-
methylated. In contrast, Pomc gene had relatively less methylation in the pituitary. 
Furthermore, in the corticotrope cell line AtT20 in which Pomc was highly expressed, 
the promoter region was free of DNA methylation. 
 
Figure 17. Pomc DNA methylation status in different tissues. Bisulfite sequencing analysis 
using DNA from different mouse tissues (6-week-old) including pituitary, hypothalamus, 
hippocampus, prefrontal cortex (PFC), adrenal gland, kidney, liver, spleen and thymus revealed a 
tissue-specific DNA methylation pattern. In normal Pomc non-expressing tissues such as kidney, 
thymus and adrenal, Pomc was hyermethylated at the distal promoter, especially at the region 
ranging from CpG6 to CpG8.  
3.2.4 DNA methylation of Pomc pseudogene 
In the early stage of our research, we found that te DNA methylation pattern in exon 
3 (CGI 2) always displayed an all-or-nothing pattern. In short, if one CpG residue was 
unmethylated in the clone, all the CpGs were totally free of methylation. In contrast 
however, if one CpG residue was methylated, all the CpGs in the clone were fully 
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methylated. Careful sequence analysis detected however slight difference in DNA 
sequence between the two classes of clones. A sequence blast was performed, and we 
found that the fully methylated sequence belonged to the Pomc pseudogene (also 
known as Pomc2 or Pomc-ps1) which locates to chromosome 19 in the mouse 
genome. Sequence alignment between Pomc and its pseudogene was performed and 
the results showed that this non-transcribed Pomc pseudogene was a homology of 
Pomc exon 3 with an identity of 90% (data not shown). 
3.3 DNA methylation controls Pomc gene expression 
Given the role of DNA methylation in controlling gen  expression, we next examined 
whether methylation alone is sufficient to repress Pomc gene activity. Bisulfite 
sequencing results showed differential DNA methylation pattern between ELS and 
controls at the Pomc distal promoter, especially in the region ranging from CpG 6 to 
CpG 8. Pomc reporter constructs with methylated or unmethylated CpGs were 
transfected into the AtT20 mouse pituitary cell line. In this experiment, selectively 
methylated CpG 6-8 induced a 43% reduction of P mc promoter activity, while 
deletion of this region diminished reporter activity by 68% (Figure 18B). These 
results demonstrated the functional importance of this region for regulation of Pomc 
gene expression. We also examined Pomc reporter activity after in vitro methylation 
of the entire promoter, including the core promoter and the distal promoter. Such 
methylation completely abolished luciferase activity. Taken together, these findings 
suggested that DNA methylation at CpG 6-8 is critical for controlling Pomc gene 
expression. Bisulfite sequencing proved the success of ite-directed DNA methylation 
(Figure 18C).  
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Figure 18. DNA methylation controls Pomc gene expression. (A) Schematic representation of 
Pomc luciferase constructs. The parental Pomc-Luc construct (mock) contains the entire mouse 
Pomc promoter. M.CpG6-8 indicates that only CpG 6-8 were in vitro methylated by site-directed 
DNA methylation using a CpG-free vector. ∆CpG 6-8 is devoid of CpG 6 to 8. M.All-CpG 
indicates that all the CpGs in the Pomc promoter were completely methylated by CpG methylase 
SssI. ∆Distal-Prom lacks the entire distal promoter. (B) Entire vector or site-specific promoter 
(CpG 6-8) methylation reduced reporter activity by 99% and 40%, respectively. Deletion of either 
CpGs 6-8 or the entire distal promoter reduced report r activity by 68% and 90%, respectively, in 
AtT20 cells. (C) Bisulfite sequencing confirmed the success of site-directed DNA methylation. 
Data are mean ± SD, three independent experiments were performed.  *p < 0.05 (t-test). 
Hypothalamic derived peptides corticotrophin-releasing-hormone (CRH) and 
arginine vasopressin (AVP) stimulate transcription of Pomc and secretion of ACTH in 
vivo and in ACTH producing pituitary tumor AtT20 cells.  Previous studies showed 
the importance of the distal promoter for the regulation of Pomc activity after CRH 
and AVP stimulation. In our study, we questioned whether DNA methylation in the 
Pomc distal promoter could affect AVP and CRH-dependent stimulation of Pomc 
expression. From the literature (Ventura et al., 1999) and our RT-PCR experiment, we 
know that AVP v1b receptor expression is barely detectable in normal AtT20 cells. 
To overcome this problem, a new AtT20 cell line with v1b receptor stably expressed 
was used. In this cell line, the mouse AVP v1b receptor gene was intergrated into the 
mouse genome resulting in stable expression of the mouse v1b receptor. Methylated 
and unmethylated Pomc reporter were transfected into AtT20 cells (AVP v1bR), 24 
hours after transfection, the cells were treated with the peptides AVP (10-7 M), CRH 
(10-8 M) or both. After 2 hours of treatment, luciferase activity was measured. 
According to the results in Figure 19, if the reporter is unmethylated, the Pomc 
promoter activity was increased by 38%, 22% and 67%respectively upon CRH, AVP 
or CRH+AVP treatment in the cultured cells compared with the non-treated control. 
However, if the Pomc reporter was methylated at CpG 6-8, CRH treatment alone 
failed to activate Pomc expression. On the contrary, AVP treatment alone can still 
increase the Pomc mRNA expression by 22% when compared with the non-treated 
control. A synergic effect of Pomc promoter activation (31% increases) was also 
observed when the methylated reporter was treated with both AVP and CRH. Taken 
together, DNA methylation plays a critical role in the regulation of Pomc gene 
expression both under basal condition and activated con itions. 
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Figure 19. DNA methylation at CpGs 6-8 strongly blocked Pomc activation stimulated by 
CRH, but not by AVP. AVP (10-7 M) and CRH (10-8 M) activated Pomc promoter activity when 
the Pomc reporter was free of DNA methylation. If the Pomc reported was site-directed 
methylated at CpG 6-8, CRH treatment alone failed to stimulate Pomc mRNA expression. In 
contrast, AVP or AVP+CRH treatment increased Pomc luciferase activity compared with non-
treated control. Values represent mean ± S.D. Three ind pendent experiments were performed. 
The asterisks indicate significant difference. (*, P<0.05) 
 
3.4 MeCP2 binds to the Pomc promoter and represses gene 
activity 
3.4.1 MeCP2 represses Pomc gene expression 
In our previous results (Figure 18), we proved that DNA methylation could repress 
Pomc gene expression. The next question was, by which mechanism does DNA 
methylation repress Pomc gene expression? It is generally accepted that DNA 
methylation at CpG dinucleotides (
m
CG) is interpreted by a family of methyl CpG-
binding domain (MBD) proteins. These epigenetic readers (except MBD4) can serve 
as an epigenetic platform. Histone deacetylases (HDACs) and DNA 
methyltransferases (DNMTs) can be recruited to confer transcriptional repression and 
gene silencing. After cotransfecting a series of MBD family proteins with the 
methylated reporter plasmid into AtT20 cells, we found that MBD1, MBD2 and 
MBD3 have moderate effects on DNA methylation-directed Pomc repression. In 
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contrast, we found that the founding member of MBD family protein, MeCP2, 
significantly suppressed Pomc gene activity (Figure 20A).  
 
Figure 20. MeCP2 strongly represses Pomc gene expression in vitro and in vivo.  (A) After 
cotransfecting a series of MBD proteins with methylated reporter plasmid into AtT20 cells, we 
found that MeCP2 significantly suppressed Pomc gene activity, while MBD1, MBD2 and MBD3 
had moderate effect. (B) Pomc mRNA level between wild type and MeCP2 KO was tested by 
qRT-PCR. The results showed a two-fold increase of Pomc mRNA levels in MeCP2 KO mouse 
pituitary compared with controls. 
Since these experiments were done under over-expression, we were interested to 
know whether MeCP2 is expressed in pituitary cells. RT-PCR, western blot and 
immunohistochemistry results revealed the presence of MeCP2 in pituitary cells 
(Figure 21A). To examine the repressive role of MeCP2 in vivo, pituitaries from 
MeCP2 knockout mice were subjected to gene expression analysis. The results 
confirmed the repressor role of MeCP2 for Pomc expression as evidenced by over 2-
fold increased mRNA levels compared with wild type mice (Figure 20B). 
 
Figure 21. MeCP2 is expressed in pituitary cells. (A) RT-PCR and western blot results showed 
that MeCP2 is expressed in mouse pituitary and the pituitary cell line-AtT20 both at the mRNA 
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and protein levels. Mouse hypothalamic tissue and the hypothalamic cell line N6 were used as 
positive controls. (B) MeCP2 is strongly expressed in the cell nuclei of the mouse pituitary and 
colocalizes with ACTH-positive cells. Scale bar, 50 µm. 
To further investigate the distribution of MeCP2 inthe mouse pituitary, 
immunohistochemistry experiments were performed using antibodies against total 
MeCP2 (red) and ACTH (green) in naïve mouse pituitary slides. The results in Figure 
21B showed that MeCP2 is ubiquitously expressed in the cell nuclei of the mouse 
pituitary and colocalized with ACTH positive cells. 
 
3.4.2 MeCP2 binds to the Pomc promoter in vitro 
To investigate whether MeCP2 can be directly bound to the Pomc promoter, 
electrophoretic mobility shift assay (EMSA) experiments were performed using 
recombinant GST-MeCP2 protein. According to previous reports, MeCP2 DNA 
binding depends on two criteria: firstly, MeCP2 prefe ntially binds to methyl-CpG 
sites and secondly, binding is increased in case A/T bases ([A/T≥4]) are present 
adjacent to methyl-CpG. The sequence [A/T≥4] was found previously to be essential 
for high-affinity binding at selected sites and at known MeCP2 target regions such as 
in the Bdnf and Dlx6 genes. Based on these MeCP2 binding criteria, Pomc DNA 
sequences of far upstream 5’ UTR, promoter (CGI 1) and exon3 (CGI 2) were 
analyzed. The results revealed that only the DNA sequence in the distal promoter 
fulfilled the two criteria for MeCP2 binding. The far upstream promoter failed the test 
because of the very low density of CpG sites in that region. In contrast, exon3 
behaved differently. Although there were plenty of CpG sites (CGI 2), A/T ([A/T≥4]) 
runs were rarely found adjacent to methyl-CpG. Three pairs of oligonucleotides were 
designed for the EMSA experiments. Oligonucleotide EMSA1 was located in the 
distal promoter which contained CpG 6 together with 3 A/T runs adjacent to CpG 6. 
EMSA2 was located next to EMSA1 which covered CpG 7 and CpG 8. As a negative 
control, we also designed a pair of oligonucleotides named control (Ctrl) in the 
promoter spanning CpG 14-16, but in this sequence there were no A/T ([A/T≥4]) runs 
adjacent to CpG dinucleotides (Figure 22A).  
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Figure 22. MeCP2 is bound to the Pomc promoter in vitro. (A) Schematic diagram of the Pomc 
promoter. The distribution of CpG residues is indicated according to their position by vertical 
bars. The positions of the respective oligonucleotides used for EMSA experiments are shown. (B) 
EMSA experiments showed that MeCP2 recognized specifically methylated CpG 
oligonucleotides. MeCP2 was bound strongly to methyla ed, but not to unmethylated EMSA1 and 
EMSA2 oligonucleotides as well as the positive contr l. Self-competition experiments and pre-
incubation with the MeCP2 antibody proved the specificity of MeCP2 binding to the methylated 
EMSA1 and EMSA 2. (C) MeCP2 showed no binding in the middle of the Pomc promoter 
(Control) irrespective of its methylation status. (D) The positive control shows that MeCP2 
preferentially binds to methylated oligonucleotides. Representative autoradiograms (n = 3 
independent experiments each) are shown. 
Sense and antisense oligonucleotides were first slowly annealed to form a double 
strand and then in vitro methylated. Both methylated and unmethylated 
oligonucleotides were subjected to an end-labeling step with 35S. End-labeled 
oligonucleotides together with GST-MeCP2 protein were loaded on the PAGE gel 
and were fractionated. 
The results of the EMSA experiments in Figure 23B agree with previous 
evidence for high affinity MeCP2 binding, to methylated CpGs adjacent to A/T sites. 
MeCP2 specifically bound to the region spanning CpG 6 to CpG 8 (EMSA1 and 
EMSA2), with an affinity (KD =6.48 nM and 5.86 nM respectively), which is 
comparable to the positive control (Figure 22D). Incontrast the control 
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oligonucleotide in the middle of the Pomc promoter showed no binding at all 
irrespective of the methylation status (Figure 22C). The specificity of the 
protein/DNA complex was further confirmed by a super shift assay, in which the 
protein/DNA complex disappeared during the gel electrophoresis upon addition of 
MeCP2 antibody. Self-competition tests were also performed using an excess (1:10, 
1:100, 1:1000) of unlabelled methylated or unmethylated oligonucleotides. The 
results showed that DNA binding was gradually reduc with increased amount of 
methylated oligonuceotide, while the unmethylated oligonucleotide had much less 
effect.   
To further decipher the importance of methyl-CpG and the adjacent A/T sites for 
MeCP2 binding, a series of mutations were generated.  The set of mutations tested is 
shown in the left part of Figure 23, with the parent oligonucleotide sequence depicted 
above. In the case of EMSA1 (CpG 6), A/T runs were essential for MeCP2 binding. 
For example, if AT3 was mutated alone, the binding was reduced by 75%, and if AT2 
and AT3 were mutated together, only 14% binding remained compared with the wild 
type. Furthermore, if AT runs were completely mutated; the MeCP2 binding was 
almost abolished (Figure 23A). In the case of EMSA2, it might have a different 
binding mechanism compared with EMSA1 because there w  two CpG sites (CpG 7 
and CpG 8) and only one A/T run in the oligonucleotide. As shown in Figure 23B, 
mutations occurring in one of the CpGs impaired protein/DNA complex formation, 
while mutations in both CpG 7 and CpG 8 completely destroyed the protein/DNA 
complex.  The AT run was also a key element for MeCP2 binding in EMSA2. As 
shown in Figure 23B, the DNA/protein complex was strongly impaired after mutation 
of A/T sites adjacent to CpG dinucleotides. 
In summary, in vitro binding experiments showed that MeCP2 was efficiently 
bound to sequences present at the Pomc distal promoter region spanning CpG 6 to 
CpG 8, while MeCP2 showed less binding to other parts, such as the proximal 
promoter (CpG 14-16). Mutational studies revealed that both the methylated CpG(s) 
and the AT runs were essential for high affinity MeCP2 binding. 
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Figure 23. Methylated CpGs and AT runs were essential for MeCP2 binding to Pomc 
promoter derived oligonucleotides. (A) Binding specificity of MeCP2 for EMSA1 was 
investigated by base substitutions of AT clusters adjacent to the methylated CpG. The sequence of 
the parent oligonucleotides is listed above the scheme. The results indicated a strong decline of 
MeCP2 binding resulting from the absence of AT sequences adjacent to methylated CpG 6. (B) 
Binding specificity of MeCP2 for EMSA2 was investigated by mutagenesis of either CpG(s) or 
AT cluster adjacent to methylated CpG residues. The results indicated a strong decline of MeCP2 
binding for mutated CpG sites or mutated AT sequences flanking  methylated CpGs. 
 
3.4.3 MeCP2 represses Pomc gene expression in vivo 
Chromatin immunoprecipitation (ChIP) is a technique to investigate the binding of a 
particular protein of interest to chromatinized DNA. In our experiment, we sought to 
confirm the repressive function of MeCP2 at the Pomc locus in vivo. A sequential-
ChIP experiment from mouse pituitary was performed to prove this hypothesis. The 
first (primary) round of the ChIP was carried out wi h antibodies against acetylated 
histone H3 (H3Ac), a mark of transcriptional active chromatin, or dimethylhistone H3 
Lys-9 (H3K9me2), a mark of transcriptional repressive chromatin. The anti-C-
terminal MeCP2 antibody was used for the second (secondary) round of ChIP, which 
we performed on half of the product of the primary ChIP; the remaining product from 
the first ChIP was saved for analysis of the primary ChIP. DNA recovered from both 
ChIP steps was analyzed by real-time PCR for the presence of the Pomc promoter. By 
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doing so, we were able to simultaneously evaluate the activity of Pomc as well as 
MeCP2 occupancy at the Pomc promoter. Two pairs of primers were designed for this
ChIP experiment. The first primer pair was located in the Pomc distal promoter region 
spanning CpG 6 and CpG 10 and producing a 154 bp PCR amplicon. As a control, the 
second primer pair was designed in the coding region (exon3) which lies 6 kb 
downstream (Figure 24A). 
 
Figure 24. MeCP2 is bound to the repressed state ofthe Pomc promoter in vivo Seq-ChIP was 
performed on pituitary chromatin isolated from naїve mice. (A) Schematic representation of the mouse 
Pomc gene indicating the position of PCR-amplified regions in the ChIP experiment. (B) More Pomc 
DNA was recovered when the primary ChIP was conducted with anti-acetyl histone H3 (H3Ac) than 
with anti-dimethyl-histone H3 Lys9 (H3K9me2). (C) Secondary ChIP with anti-C-terminal MeCP2 on 
the samples recovered from B indicated that MeCP2 preferentially associates with dimethyl-histone H3 
Lys-9 at the Pomc promoter. Values represent mean ± SD. Three independent experiments were 
performed. The asterisks are used to indicate significa t difference (*, P < 0.05). 
 
When we performed the primary ChIP, we recovered more Pomc DNA with 
anti-acetyl histone H3 than with anti-dimethyl histone H3 Lys-9 (Figure 24B). 
However, when we performed the second round ChIP with anti-MeCP2, we recovered 
significantly more Pomc from chromatin that had been initially immunoprecipitated 
with anti-dimethyl-histone H3 Lys-9 than from chromatin that had been initially 
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immunoprecipitated with anti-acetyl histone H3 (Figure 24C). In summary, the results 
from Seq-ChIP indicated that MeCP2 is preferentially associated with the 
transcriptionally inactive, dimethyl-histone H3 Lys-9 marked Pomc promoter in mice 
pituitaries. 
 
3.4.4 MeCP2 recruits repressor complexes to the Pomc 
promoter  
MeCP2 suppresses gene transcription by recruiting corepressors, such as HDACs and 
DNMTs, to its target DNA binding sites. To determine which corepressors coexist 
within the same protein complex resident at the promoter region of Pomc, sequential 
ChIP assays were performed. In this sequential ChIP assay, an initial ChIP was 
performed with an antibody that recognizes MeCP2. The precipitated chromatin-DNA 
complex was washed and eluted, and a second immunoprecipitation (IP) was 
performed with MeCP2, Hdac1, Hdac2, Hdac4, Dnmt1, Dnmt3a, Dnmt3b or control 
istope IgG antibodies. When the first ChIP was performed with anti-MeCP2, the 
second ChIP showed the presence of Hdac2, Dnmt1, and to a lesser extent Hdac1, in 
the MeCP2-DNA complex (Figure 25). In contrast, the Pomc promoter was not 
enriched for Hdac4, Dnmt3a and Dnmt3b binding. The sp cificity of these results was 
supported by performing the sequential ChIP experimnt in the reverse order (data not 
shown).  
ChIP was first performed with antibodies against either MeCP2, corepressors 
(HDACs and DNMTs) or control rabbit IgG on chromatin derived from naïve mouse 
pituitaries. Immunocomplexes were dissociated from the beads and 50% of the first 
immunoprecipitation (IP) were reverse cross-linked and subjected to PCR analysis. 
The remaining eluate of the first IP reaction was subject to a second round of ChIP 
with an antibody against MeCP2 or control rabbit IgG. PCR analysis was performed 
on the eluates both from the first ChIP and second ChIP. The results revealed that 
Hdac1, Hdac2 and Dnmt1 exist in Pomc distal promoter region in the first ChIP. The 
co-occupancy of Hdac1 with MeCP2, Hdac2 with MeCP2 and Dnmt1 with MeCP2 
was proved by the second ChIP with MeCP2. 
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Figure 25. MeCP2 is associated with repressor complexes (HDACs and DNMTs) at the Pomc 
promoter region. Sequential ChIP assays were performed after an initial immunoprecipitation (IP) 
with anti-MeCP2. After a second IP with anti-Hdac1, anti-Hdac2, or anti-Dnmt1, DNA from the 
distal promoter, but not from the coding region (exon3) could be amplified. No DNA was 
recovered following immunoprecipitation by Hdac4, Dnmt3a, Dnmt3b or isotype IgG antibodies.  
 
3.5  Phosphorylation of MeCP2 in pituitary cells  
3.5.1 Depolarization dependent MeCP2 phosphorylation in 
pituitary cells  
Protein phosphorylation is an important posttranslation l modification that can 
modulate the function of a protein by adding a phosate group to serine, tyrosine, or 
threonine residues. Previous results showed that phosphorylation of MeCP2 at serine 
421 in cultured rat neurons can precede the release of M CP2 from the Bdnf promoter 
resulting in an increase in BDNF expression (Zhou et al., 2006; Tao et al., 2009). We 
wondered whether such phosphorylation of MeCP2 is also present in pituitary cells. 
To address this question, immunocytofluorescence (ICC) experiments were 
performed using an antibody against total MeCP2, which recognizes MeCP2 
irrespective of its phosphorylation status and an antibody against pS438 of MeCP2 
(which is homologous to S421 MeCP2 in rat) in pituitary primary cells. Double 
staining experiments using antibodies against MeCP2 and ACTH, the later is a marker 
for pituitary corticotrope cells, revealed the ubiquitous expression pattern of MeCP2 
in pituitary cells with higher expression levels in corticotropes (Figure 21 and 26A). 
Moreover, MeCP2 was phosphorylated at serine 438 in cultured mouse primary 
pituitary cells upon membrane depolarization by 55 mM KCl. Under basal conditions, 
the pS438 MeCP2 signal was barely detectable. In contrast, when primary cells were 
subjected to membrane depolarization using elevated levels of extracelluar potassium 
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to activate L-type voltage-sensitive calcium channels (L-VSCCs), MeCP2 S438 
phosphorylation could be readily detected in cultured mouse pituitary cells (Figure 
26B).  
 
 
Figure 26. MeCP2 is phosphorylated at serine 438 inpituitary primary cells upon membrane 
depolarization. (A) Total MeCP2 (red) showed similar levels of immunoreactivity under different 
conditions. MeCP2 colocalizes with the corticotrope c ll marker ACTH (green) in primary 
pituitary cells. (B) MeCP2 is phosphorylated at serin  438 after KCl treatment of primary pituitary 
cells. Pre-treatment of the cells with a CaMKII inhibitor prevented the increase of phospho-
MeCP2 after membrane depolarization by KCl treatmen. Scale bar, 10 µM. 
Previous research showed that cells treated with KCl undergo calcium influx 
resulting in activation of calmodulin-dependent Protein Kinase II (CaMKII). To 
address this question, pituitary primary cells were treated with 55 mM KCl for 1 hour 
and the activity of phospho-CaMKII, which is the activated form of CaMKII, was 
monitored by immunostaining. As shown in Figure 27A, the phosphorylated form of 
CaMKII was significantly increased after KCl treatment without influencing the total 
level of CaMKII (Figure 27B). Previous research revealed that MeCP2 
phosphorylation was mediated by CaMKII activity, therefore we asked whether 
pS438 phosphorylation was affected if CaMKII activity is blocked by 
pharmacological treatment. The results supported th role of CaMKII in the mediation 
of MeCP2 phosphorylation on serine 438 as evidenced by reduced pS438 MeCP2 
immunostaining when the primary cells were pre-treated with a CaMKII inhibitor 
before KCl stimulation. 
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Figure 27. Phospho-CaMKII immunostaining was increased after membrane depolarization 
of primary pituitary cells. (A) KCl treated pituitary primary cells showed increased pCaMKII 
(red) and ACTH (green) staining as compared with the non-treated condition. Pre-treatment with a 
CaMKII inhibitor prevented the increase of phospho-CaMKII immunoreactivity after membrane 
depolarization by KCl treatment. (B) In contrast, total CaMKII immunoreactivity was unchanged 
under both conditions. Scale bar, 5µM.  
 
Given the heterogeneous nature of pituitary primary cells, we asked whether 
phosphorylation of MeCP2 at serine 438 could take place in the homogeneous 
corticotrope cell line-AtT20.  
 
Figure 28. MeCP2 is phosphorylated at site 438 in AtT20 corticotrope cells upon membrane 
depolarization. Western blots of whole cell extracts from AtT20 cells demonstrated an increased 
level of phosphorylation of MeCP2 at serine 438 when c lls were depolarized by KCl. CIP 
treatment proved the specificity of the pS438 MeCP2 antibody. Total MeCP2 levels remained the 
same for all testing conditions. 
Immunoblot analysis of MeCP2-S438 phosphorylation in corticotrope AtT20 
cells showed that depolarization increased levels of MeCP2-pS438 immunoreactivity 
when compared with controls without influencing levels of total MeCP2. To confirm 
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the specificity of pS438 MeCP2, calf intestinal phosphatase (CIP) treatment was 
carried out to dephosphorylate MeCP2 residues before primary antibody incubation. 
After phosphatase treatment, the pS438 MeCP2 antibody can not detect any signal 
any more. Total MeCP2 signal was not affected by this treatment (Figure 28).  
 
3.5.2 Phosphorylation of MeCP2 at S438 reduces Pomc 
promoter occupancy 
As already shown, MeCP2 overexpression suppresses methylated Pomc reporter 
activity; we further hypothesized that Pomc expression is regulated by MeCP2 
phosphorylation. To address this hypothesis, CpG 6−8 methylated Pomc reporter 
plasmids were cotransfected with the expression vector MeCP2, constitutively active 
CaMKII, or MeCP2 together with CaMKII in AtT20 cells.  MeCP2 transfection alone 
reduced Pomc reporter activity, while, CaMKII has the opposite effect. When MeCP2 
was cotransfected with CaMKII, we observed complete r versal of the repression by 
MeCP2. To further investigate the role of phosphorylation of MeCP2 at serine 438 in 
regulating Pomc gene activity, a Flag-tagged mutant MeCP2 expression plasmid 
(S438A) was constructed, in which serine 438 was replac d by alanine. As a 
consequence, MeCP2 can not be phosphorylated at this si e any more. When AtT20 
cells were transfected with MeCP2 (S438A) in the absence or presence of CaMKII, 
the reporter activity was repressed by MeCP2 (S438A), while cotransfection of 
CaMKII could not reverse MeCP2-directed repression any more (Figure 29A).  
Previous reports indicated that phosphorylation of MeCP2 at serine 421 (pS438 
in mouse) can derepress gene activity by loss of MeCP2 binding from its target DNA 
sequence. To test whether MeCP2 occupancy is altered upon membrane 
depolarization at the Pomc locus, ChIP experiments were carried out using CpG 6−8 
methylated reporter constructs in control or membrane-depolarized cells. The results 
showed a strong reduction of MeCP2 occupancy and increased Pomc luciferase 
activity following depolarization, while pretreatment with a specific CaMKII inhibitor 
reversed the depolarization-induced dissociation (Figure 29B). 
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Figure 29. Phosphorylation of MeCP2 at serine 438 can rescue Pomc expression by 
promoting dissociation of MeCP2 from the Pomc promoter. (A) CaMKII modulates repressive 
actions of MeCP2 at the Pomc promoter. Cotransfecting a constitutively active CaMKII plasmid 
with a Pomc site-dircted methylated vector stimulated Pomc expression and overrided the 
repressive effects of further cotransfection with MeCP2. Activated CaMKII could not rescue 
Pomc expression when cotransfected with the mutated form MeCP2 (S438A). (B) Membrane 
depolarization relieved MeCP2 occupancy at the Pomc promoter. AtT20 cells were depolarized 
with 55 mM KCl (1 hour). ChIP experiments showed reduced MeCP2 occupancy at Pomc 
promoter (black bar, left), paralleled by increased Pomc luciferase activity of the promoter (gray 
bar, right). Pretreatment of AtT20 cells with a CaMKII inhibitor reversed these effects. Data are 
mean ± SD. Three independent experiments were performed.  
 
3.5.3 AVP elicits MeCP2 phosphorylation in pituitary cells 
Previous research showed that AVP actives Pomc mRNA expression through calcium 
pathways. We hypothesized that CaMKII activity might be altered during AVP 
treatment in primary pituitary cells. To address thi  question, pituitary primary cells 
were treated with AVP (10-7 M) for 2 hours, the activity of phospho-CaMKII was 
monitored by immunostaining. As shown in Figure 30A, the phosphorylated form of 
CaMKII was significantly increased after AVP treatment without influencing the total 
levels of CaMKII. As we have already shown that MeCP2 phosphorylation is 
mediated by CaMKII activity, we hypothesized that MeCP2 could be phosphorylated 
when primary pituitary cells were treated with AVP peptide. The results showed that 
this was indeed the case. Interestingly, most of the pS438-MeCP2 positive cells 
colocalized well with ACTH suggesting that MeCP2 phosphorylation at serine 438 
occurred predominantly in corticotrope cells (Figure 30B). The reason for this result 
could be explained by the fact that the AVP v1b receptor only exists in corticotrope 
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cells in the pituitary. Pre-incubation with 10-6 M SSR149415, a specific antagonist of 
the v1b receptor, completely abolished AVP-induced MeCP2 phosphorylation.  
 
Figure 30. AVP induced MeCP2 phosphorylation and dissociation from the Pomc promoter 
region. (A) Immunostaining of total and activated p-CaMKII in primary pituitary cells. AVP 
treatment activated p-CaMKII without changing the level of total CaMKII. Pretreatment of the 
cells with the AVP v1b receptor antagonist SSR149419 completely abolished AVP induced 
activation of p-CaMKII. Both CaMKII and p-CaMKII (red) colocalized with the corticotrope cell 
marker ACTH (green). Scale bar: 10 µM. (B) AVP induced MeCP2 phosphorylation at serine 438 
without altering total MeCP2 level. Scale bar: 10 µM (C) AVP treatment of AtT20 cells relieved 
MeCP2 occupancy at the Pomc promoter. AtT20 cells were treated with 100 nM AVP for 2 hours. 
ChIP experiments showed reduced MeCP2 occupancy at the Pomc promoter (black bars, left), 
paralleled by increased Pomc luciferase activity of the promoter (gray bar, right). Pretreatment of 
AtT20 cells with SSR149415 reversed these effects. Data are mean ± SD. Three independent 
experiments were performed. 
 
Next we asked whether AVP can induce MeCP2 phosphorylation in corticotrope 
cells. To answer this question, homogeneous corticotrope AtT20 cells were used to 
monitor MeCP2 phosphorylation level using immunostaining.  Previous research 
showed that AVP activates Pomc expression through binding to its specific V1b 
receptor at the corticotrope cell membrane, and triggers intracellular calcium influx. 
However, from the literature (Ventura et al., 1999) and our experiments, we know that 
AVP v1b receptor expression is barely detectable in normal AtT20 cells. To solve this 
problem, an AtT20 cell clone with v1b receptor stably expressed was used. 
Corticotrope AtT20 cells were treated with 10-7 M AVP or DMSO for 2 hours. After 
treatment the cells were fixed and stained with MeCP2 and ACTH. As the results 
show in Figure 31, pS438-MeCP2 can only be detected when AtT20 cells were 
treated with AVP. Pre-treatment of cells by SSR149415 half an hour before AVP 
treatment completly abolished AVP-induced MeCP2 phos rylation in AtT20 cells 
suggesting the specificity of AVP for MeCP2 phosphorylation.   
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Figure 31. AVP induced MeCP2 phosphorylation in AtT20 (v1bR) cells.  AVP induced 
MeCP2 phosphorylation at serine 438 through binding to the v1b receptor. Nuclear staining of p-
MeCP2 (red) colocalized with ACTH (green). Scale bar: 10 µM 
AVP-induced phosphorylation of MeCP2 at serine 438 can also reduce MeCP2 
occupancy at the Pomc promoter as tested by ChIP experiments. CpG 6−8 methylated 
Pomc reporter was transfected into the AtT20 (v1b receptor expressed) cell line. 24 
hours after transfection, the cells were treated with 10-7 M AVP peptide for 2 hours. 
Then the cells were harvested, fixed and sonicated to obtain the DNA fragments in the 
size ranging from 200 to 500 bp. ChIP experiments were performed using the 
antibody against total MeCP2, in parallel, luciferase assays were carried out to 
monitor Pomc promoter activity. To recover Pomc fragment only from the transfected 
reporter, the forward ChIP primer targeted the vector backbone, and the reverse 
primer was located in the Pomc insert. The results showed a 29% of reduction of 
MeCP2 occupancy and increased Pomc luciferase activity following AVP treatment. 
Pretreatment of AtT20 cells with SSR149415 completely blocked the dissociation of 
MeCP2 due to AVP treatment (Figure 30C).  
3.5.4 Early life stress induces phosphorylation of MeCP2 in the 
pituitary  
Previous results showed that MeCP2 is phosphorylated in pituitary cells upon 
membrane depolarization or AVP stimulation. We sought to know whether MeCP2 
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phosphorylation status is altered after early life str ss in mouse pituitary sections.  To 
address this issue, immunohistochemistry was performed on formalin fixed paraffin 
embedded pituitary sections obtained from ELS and control mice. The results 
revealed no differential regulation in total MeCP2 protein in the pituitary between 
ELS and control mice (data not shown).  
 
Figure 32. Early life stress induces phosphorylation of MeCP2 in mouse pituitary. ELS led to 
increased immunostaining of pS438-MeCP2 (red) and ACTH (green) in the anterior pituitary of 3-
month-old mice. pMeCP2 is colocalized with ACTH, which is the marker for pituitary 
corticotrope cells. White arrow heads indicate positive pS438-MeCP2 staining. The images that 
are shown are representative of five mice per group. Scale bar: 50 µM 
However, comparing pS438 MeCP2 immunoreactivity revealed an increased 
immunostaining of pS438-MeCP2 in ELS mice compared with controls. Interestingly, 
most pS438-MeCP2 positive cells were colocalized well ith ACTH. This supports 
our hypothesis that the early-life stress paradigm produced increased levels of AVP 
from the PVN of the hypothalamus which induced a tissue-specific phosphorylation 
of MeCP2.  
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3.6 Reduced occupancy of MeCP2 after ELS 
3.6.1 ELS did not affect the corticotrope cell number 
Early life stress leads to higher levels of Pomc mRNA expression in the pituitary. 
ACTH, which is enzymatically cleaved from Pro-POMC in pituitary corticotrope cells, 
was also upregulated after early maternal separation. As we know, pituitary cells 
proliferate postnatally. We wondered whether early life adversity could affect the 
development of corticotrope cells.  
 
Figure 33.  Corticotrope cell number is not altered during early life stress. Representative 
pictures of immunostaining showed no difference in corticotrope cell ratios between control (Ctrl) 
and early life stress (ELS) in 3-month old pituitaries. DAPI (blue) staining was used to mark the 
cell nuclei in all cells, while ACTH (green) positive cells indicated the corticotrope cells in the 
anterior pituitary. Scale bar: 50 µM. (B) The number of labeled cells with DAPI (total number) 
and ACTH (corticotrope cell) in 10-day old and 3-month old mice pituitaries. Pituitary slides (8 
sections/animal, 5 mice per group) 
To answer this question, immunohistochemistry experim nts were performed 
using an antibody against ACTH to mark corticotrope cells in the anterior pituitary 
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and DAPI to stain the total cell population. The total cell number of anterior pituitary 
and ACTH-positive cells were counted and compared between control and ELS mice. 
Pituitary slides (8 sections/animal, 5 mice per group) from10-day and 3-month-old 
mice were used for this experiment (Figure 33). Theresults revealed no difference in 
the ratio of the corticotrope cells with 4.56 ± 0.15 in the control group and 4.65 ± 0.31 
in the ELS group at PND 10 and ratios of 3.93 ± 0.16 and 3.95 ± 0.14 at 3 months of 
age, respectively. In summary, these immunohistochemistry results imply that ELS 
did not affect postnatal development of the corticotrope cell population. 
 
3.6.2 ELS reduces MeCP2 occupancy at the Pomc promoter 
Previous EMSA experiments indicated that MeCP2 preferentially binds to methylated 
DNA sites in the Pomc distal promoter region. Sequential ChIP experiments 
performed in mouse pituitary revealed that MeCP2 was associated with a 
transcriptional inactive state of the Pomc promoter. In addition, bisufite sequencing 
results showed that early life stress (ELS) induced hypomethylation at the Pomc distal 
promoter.  Taken together, we speculated that the diff rence in DNA methylation 
would result in differential occupancy of MeCP2 at thePomc promoter, which in turn 
will affect Pomc mRNA expression. To test this hypothesis, in vivo ChIP experiments 
were performed using mouse pituitaries from 6 weeks old mice. Two antibodies were 
used in this in vivo ChIP: activated RNA Pol II, which is an indicator f Pomc 
transcription and C-terminal MeCP2 (antibody against total MeCP2). Two pairs of 
primers were designed for this ChIP experiment. Thefirst primer pair was located in 
the Pomc distal promoter region spanning CpG 6 and CpG 10 and producing a 154 bp 
PCR amplicon. As a control, the second primer pair w s designed in the coding region 
(exon3) which lies 6 kb downstream (Figure 24A). 
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Figure 34. ELS altered MeCP2 and RNA polI II occupancy at the Pomc locus in 6 weeks old 
mice pituitaries. (A) ChIP analysis using the pituitaries of control and ELS mice revealed 
increased binding of RNA pol II at the Pomc promoter region. (B) ChIP analysis showed that ELS 
mice displayed decreased binding of MeCP2 at the Pomc promoter region. (C) Monitoring MeCP2 
mRNA expression levels showed no difference between pituitaries from ELS mice and control 
mice in 6 weeks old mice. Values expressed as mean ± S.E.M; ChIP, n = 8 animals/group; RT-
PCR, n = 6-8/group * P < 0.05. 
In vivo ChIP analysis revealed increased activated RNA pol II occupancy at the 
Pomc promoter of ELS mice, reflecting increased Pomc gene transcription (Figure 
34A). When we performed the ChIP experiment using ati-MeCP2 antibody, the 
results showed that total MeCP2 occupancy was reduced in the ELS group (Figure 
34B). These results agree with the findings of less DNA methylation in the ELS 
group. A statistical analysis was performed and the results demonstrated a negative 
correlation between total MeCP2 antibody and RNA Pol II binding (p < 0.05, data not 
shown). Monitoring MeCP2 mRNA expression levels showed no differences between 
pituitaries from ELS mice and control mice in 6 weeks old mice (Figure 34C). 
We also investigated MeCP2 occupancy status in 10 days old mouse pituitary. 
ELS mice also displayed reduced MeCP2 occupancy at the Pomc promoter region 
compared with control litters (Figure 35A). Although Pomc mRNA level was 
markedly increased in 10 days old mice (Figure 12, 35A), the DNA methylation level 
did not differ between control and ELS mice of this age. Given that 10 days old 
control and ELS mice have similar methylation patterns, the differences in MeCP2 
occupancy indicated that ELS-induced phosphorylation of MeCP2 at serine 438 leads 
to relief of MeCP2 occupancy from the Pomc promoter. There was no difference for 
MeCP2 mRNA expression levels between pituitaries from ELS mice and control mice 
in 10 days old mice (Figure 35C). 
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Figure 35. ELS leads to reduced occupancy of MeCP2 at the Pomc locus in 10 days old mice. 
(A) qRT-PCR analysis revealed ELS mice displayed increased level of Pomc mRNA expression 
compared with controls in 10-days old mice pituitaries. (B) ChIP analysis showed that ELS mice 
displayed decreased binding of MeCP2 at the Pomc promoter region. (C) Monitoring MeCP2 
mRNA expression levels showed no difference between pituitaries from ELS mice and control 
mice in 10-days old mice. Values expressed as mean ± S.E.M; ChIP, n = 8 animals/group; RT-
PCR, n = 6−8/group * P < 0.05. 
 
3.6.3 Early life stress reduces recruitment of Dnmt1 occupancy to 
the Pomc promoter  
Which mechanism is responsible for the loss of methyla ion during early life 
experience? As we know, the pituitary gland almost d ubles in volume during the first 
10 days of life and continutes to enlarge until adulthood. The mitosis of existing cells 
contributes to the increase in number during early postnatal development. To maintain 
DNA methylation pattern during cell mitosis, DNA methyltransferases are recruit. 
Dnmt1 is known control DNA methylation maintenance during cell division. MeCP2, 
which can directly bind to methylated or hemimethylated DNA sequence, can tether 
Dnmt1 and promote DNA methylation. Our previous experiment showed that Dnmt1 
is associated with MeCP2 at the Pomc promoter.  Early life stress leads to reduced 
MeCP2 occupancy at the Pomc promoter. We questioned whether ELS could affect 
Dnmt1 recruitment at the Pomc promoter resulting in loss of DNA methylation during 
pituitary cell proliferation.  
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Figure 36. Sequential ChIP experiment showed that ELS reduced MeCP2 and Dnmt1 
occupancy at the Pomc locus in 6 weeks old mice pituitaries. (A) The first ChIP using an 
antibody against MeCP2 revealed decreased binding of MeCP2 at the Pomc promoter region. (B) 
The second ChIP using an antibody against Dnmt1 showed that ELS mice displayed lower level 
binding of Dnmt1 at the Pomc promoter region compared with controls. (3 pituitaries were pooled, 
n = 8/group; * P < 0.05) (C) Monitoring Dnmt1 mRNA expression levels showed no difference 
between pituitaries from ELS and control mice in 6 weeks old animals. Values expressed as mean 
± S.E.M; ChIP, three pituitaries were pooled, n = 8/group; RT-PCR, n = 8/group * P < 0.05. 
 
 
Figure 37. Sequential ChIP experiment showed that ELS reduced MeCP2 and Dnmt1 
occupancy at the Pomc locus in 10 days old mice pituitaries. (A) The first ChIP using an 
antibody against MeCP2 revealed decreased binding of MeCP2 at Pomc promoter region. (B) The 
second ChIP using an antibody against Dnmt1 showed that ELS mice displayed lower level 
binding of Dnmt1 at Pomc promoter region compared with controls. (C) Monitoring Dnmt1 
mRNA expression levels showed no difference between pituitaries from ELS and control mice in 
10 days old animals. Values expressed as mean ± S.E.M; ChIP, five pituitaries were pooled, n = 
8/group; RT-PCR, n = 8/group * P < 0.05. 
To address this question, a sequential ChIP experiment was performed using the 
first antibody against MeCP2 and the second antibody against Dnmt1 for comparing 
ELS and control pituitaries. When we performed the ChIP experiment using anti-
MeCP2 antibody, the results showed that total MeCP2 occupancy was reduced in ELS 
group (Figure 36A, 37A) as we showed previously by simple ChIP both in 10-day-old 
pituitary and in 6-week-old mice (Figure 34, 35). When we performed the second 
round ChIP with anti-Dnmt1, we recovered significantly more Pomc from chromatin 
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from control mice than from ELS mice both in 10-day old and 6-weeks old mice 
pituitaries (Figure 36B, 37B). Monitoring the mRNA expression of Dnmt1 by qRT-
PCR revealed no difference in basal Dnmt1 expression levels between pituitaries from 
ELS and control mice both in 10-day and 6-week-old mice (Figure 36C, 37C).    
 
3.7 Home-made MeCP2 antibody generation 
3.7.1 Peptides used for MeCP2 antibody generation 
 
The polyclonal antibody antitotal MeCP2 that recognizes MeCP2 irrespective of its 
phosphorylation status was generated by injecting New Zealand White rabbits with 
the KLH-conjugated peptide NH2-CSMPRPNREEPVDSRTPV-CONH2 
corresponding to amino acids 480-496. The antiserum was purified by affinity-
chromatography on a column that was coupled to MeCP2 480-496 peptide, and the 
affinity-purified anti-total MeCP2 antibody was eluted. 
The polyclonal antibody MeCP2 pS438 that recognizes the phosphorylated 
serine 438 was generated by injecting New Zealand White rabbits with the KLH-
conjugated peptide NH2-CMPRGGpSLES-CONH2 (phosphor-serine). The antiserum 
was purified by affinity chromatography on a column that was coupled to 
unphosphorylated MeCP2 S438 peptide. The flow-through was then passed over a 
second column that was conjugated to phosphorylated M CP2 S438 peptide, and the 
affinity-purified anti-MeCP2 pS438 antibody was elut d. 
The polyclonal antibody MeCP2 pS97 that recognizes th  phosphorylated serine 
97 was generated by injecting New Zealand White rabbits with the KLH-conjugated 
peptide NH2-EASApSPKQR (phosphor-serine). The antiserum was purified by 
affinity chromatography on a column that was coupled to unphosphorylated MeCP2 
S97 peptide (Figure 38). 
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Figure 38. Protein sequence alignment of e1 forms of mouse, human and rat MeCP2. The 
peptides used for generation of the different MeCP2 antibodies are boxed in color. pS97 and 
pS438 phosphorylation sites are pointed out by arrows in the MeCP2 protein sequence. 
 
3.7.2 MeCP2 constructs used for antibody validation 
 
MeCP2 expression constructs were transfection into LLC-PK1 cells for testing 
MeCP2 antibodies. The position of the S97 and S438 phosphorylation site and the 
total MeCP2 site are marked in the wild type MeCP2 construct in Figure 39. Wild 
type, mutated or truncated versions of MeCP2 were tagged at their amino termini with 
the Flag-epitope. The phosphor-acceptor residue serine 97 was replaced by alanine in 
MeCP2 (S97A) and the phosphor-acceptor residue serine 438 was replaced by alanine 
as well (S438A). In the case of MeCP2∆C, the terminal 45 amino acids containing the 
recognition sequence for anti-MeCP2 were deleted. 
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Figure 39. Schematic of MeCP2 expression constructs u ed for MeCP2 antibodies validation. 
The position of the S97 and S438 phosphorylation site and the total MeCP2 site are marked in the 
wild type MeCP2 construct. Wild type, mutated or truncated versions of MeCP2 were tagged at 
their amino termini with the Flag-epitope. The phosphor-acceptor residue serine 97 was replaced 
by alanine in MeCP2 (S97A) and the phosphor-acceptor residue serine 438 was replaced by 
alanine as well (S438A). In the case of MeCP2∆C, the terminal 45 amino acids containing the 
recognition sequence for anti-MeCP2 were deleted. 
 
3.7.3 Antibody validation by western blot 
3.7.3.1 Characterization of the anti-total MeCP2 antibody 
Flag-tagged MeCP2 (0.1 µg each) expression vector was transfected into LLC-PK1 
cells and immuoblotted whole cell extracts (WCE) were tested with anti-MeCP2 
(1:1,000), a commercial MeCP2 antibody (1:1,000, Up-MeCP2), or an anti-Flag 
antibody (1:1,000). No signals were detected in mock-transfected cells, MeCP2 
transfected cells tested with the preimmune serum, or following pre-absorption of the 
MeCP2 antibodies on a GST-MeCP2 fusion protein (Figure 40). 
Similar signals were detected by anti-MeCP2 antibodies in MeCP2 transfected 
cells. In contrast to the Flag-antibody, neither of the anti-MeCP2 antibodies detected 
transfected MeCP2∆C, indicating their specificity. 
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Figure 40. Characterization of the anti-total MeCP2 antibody. 
 
3.7.3.2 Characterization of the anti-phospho MeCP2-S438    
antibody 
MeCP2 was cotransfected in the absence or presence of calmodulin kinase (CaMKII) 
or of two different forms of constitutively active calmodulin kinases [containing 
either a C-terminal truncation (CaMKII*) or a point mutation (T286D)]. Immunoblots 
were tested with either anti-MeCP2 or anti-MeCP2-pS438. Signals detected by 
MeCP2-pS438 were specific to the phosphorylated form f MeCP2 (Figure 41A).  
In the following experiment, the specificity of MeCP2-pS438 was tested. Wild 
type MeCP2 and mutated MeCP2 (S438A) were separately transfected in the absence 
and presence of CaMKII* and immunoblots were tested with anti MeCP2-pS438 or 
anti-Flag antibodies, respectively. MeCP2-pS438 detect d MeCP2 solely in the 
presence of CaMKII* and of serine 438. Retesting of the same immunoblots with the 
anti-Flag antibody proved that all samples contained comparable levels of MeCP2 
proteins (Figure 41B).  
Calf intestine phosphatase (CIP) was used to further confirm the specificity of 
the MeCP2-pS438 antibody. WCE from cells cotransfected with Flag-tagged MeCP2 
and CaMKII* were treated with calf intestine phosphatase. Preincubation with CIP 
entirely abolished the detection of MeCP2 by the MeCP2-pS438 antibody. In contrast, 
the anti-Flag antibody detected similar levels of MeCP2 expression, irrespective of 
CIP pretreatment. In parallel, we also tried to dephosphorylate the protein after SDS-
PAGE. After protein transfer, the blotting membrane was treated with CIP by 
incubation at 37 °C for 1 hour. Both methods lead to similar results (Figure 41C). 
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Figure 41. Characterization of the anti-phospho MeCP2-S438 antibody. 
 
3.7.3.3 Characterization of the anti-phospho MeCP2-S97 
antibody 
Serine 97 phosphorylation of MeCP2 occurs under rest conditions. Wild type and 
mutated MeCP2 (S97A) were transfected into LLC-PK1 cells. Immunoblots were 
tested with either anti-total-MeCP2 or anti-MeCP2-pS97. Signals detected by 
MeCP2-pS97 were specific to the phosphorylated form f MeCP2. An aliquot of 
MeCP2-pS80 (equal to pS97 in mouse) antibody (generous gift from Jifang Tao 
UCLA, USA) was used as a positive control (Figure 42).  
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Figure 42. Characterization of the anti-phospho S97-MeCP2 antibody. 
3.7.4 Antibody validation by immunocytochemistry (ICC) 
 
Immunocytochemistry experiments were performed to validate MeCP2 antibodies. To 
test the C-terminal anti-total MeCP2 antibody, wild type MeCP2 and MeCP2∆C 
expression constructs were transfected into LLC-PK1 cells. MeCP2 antibody from 
rabbit and Flag antibody from mouse were used for staining. As shown in Figure 43, 
the MeCP2 antibody detected expression of the wild type MeCP2 construct 
exclusively in the nuclei of transfected LLC-PK1 cells. By contrast, following 
expression of MeCP2∆C, no signal was detected, while the Flag antibody detected 
both MeCP2 proteins. 
In the second experiment, the specificity of MeCP2-pS97 was tested. Wild type 
MeCP2 and mutated MeCP2 (S97A) were separately transfected in LLC-PK1 cells. 
LLC-PK1 cells were fixed and incubated with anti MeCP2-pS97 and anti-flag 
antibodies. The anti-MeCP2-pS97 antibody detected the phosphorylated form of 
MeCP2 exclusively in the nuclei under resting conditions. When the residue serine 97 
was mutated to alanine, the anti-MeCP2-pS97 failed to etect any signal in the cell. 
While the flag antibody proved the successful transfection of the MeCP2-S97A 
expression plasmid to the cells (Figure 44).  
In the last experiment, the specificity of MeCP2-pS438 was tested (Figure 45). 
Wild type MeCP2 and mutated MeCP2 (S438A) were separately transfected in the 
absence and presence of CaMKII and immunostainings were tested with anti-total-
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MeCP2, anti-MeCP2-pS438 and anti-Flag antibodies. Anti-total-MeCP2 antibody can 
detect the signal irrespective of the phosphorylation status of MeCP2. MeCP2-pS438 
detected MeCP2 solely in the presence of transfected CaMKII and the wild type 
MeCP2 construct. In contrast, when the residue serine 438 was mutated to alanine, the 
anti-MeCP2-pS438 antibody failed to detect any signal. The flag antibody can still 
prove the successful transfection of MeCP2-S438A expression plasmid to the cells. 
 
Figure 43. Total MeCP2 antibody validation using immunocytochemistry. Immunostaining of 
Flag-tagged wild type and C-terminal deletion MeCP2 in LLC-PK1 cells showed that total 
MeCP2 specifically recognized the C-terminal epitope of the MeCP2 protein. Total MeCP2 
antibody failed to detect any signal from overexpression of C-terminal deletion MeCP2 (∆C-
MeCP2). The flag antibody proved the successful transfection of ∆C-MeCP2 expression plasmid 
into the cells. Scale bar: 10 µM 
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Figure 44. pS97-MeCP2 antibody validation using immunocytochemistry. Immunostaining of 
Flag-tagged wild type and mutated form (serine 97 to alanine) MeCP2 in LLC-PK1 cells showed  
pS97-MeCP2 antibody specifically recognized phosphor-serine 97 of MeCP2 protein in the cell 
nuclei. pS97-MeCP2 antibody failed to detect any signal from overexpression of mutated form 
(S97A) of MeCP2. The flag antibody proved the successful transfection of S97A-MeCP2 
expression plasmid into the cells. Scale bar: 10 µM 
 
 
Figure 45. pS438 MeCP2 antibody validation using imunocytochemistry. Immunostaining 
of Flag-tagged wild type and S438A phosphorylation site MeCP2 in LLC-PK1 cells showed 
pS438 MeCP2 specifically recognized phosphor-serine 438 of MECP2 protein in the cell nuclei. 
pS97 MeCP2 antibody failed to detect any signal from overexpression of mutated form (serine 97 
to alanine) of MeCP2. The Flag antibody proved the successful transfection of MeCP2 expression 
plasmids to the cells. Scale bar: 10 µM
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4 Discussion 
4.1 Early life stress programs HPA axis activity 
In rodents and humans, adverse experience during early life can result in long-term 
changes in neuroendocrine, behavioral and cognitive functions as well as alterations 
in metabolism. In an attempt to find out more about the detailed mechanisms 
responsible for these alterations, this study used a mouse model of early life stress 
(ELS):  3 hours daily maternal separation. Previous research showed that the first ten 
days of life is very critical time window for development of the mouse brain. So, 
interruption of the normal maternal-pup interaction during this period is considered as 
a severe stressor and determinant of mouse physiology and behavior, reflected in  
long-lasting activation of the HPA axis in C57BL/6N mice. In this study, mouse 
subjected to ELS exposure were found to have larger adrenals and a smaller thymus 
gland, both physiological correlates of prolonged activ tion of the HPA axis. In 
addition, corticosterone secretion was significantly increased for between 6 weeks and 
1 year. Further, Pomc mRNA levels in the pituitary were markedly increasd, as 
shown by qRT-PCR and in situ hybridization.    
4.2 Altered DNA methylation after ELS 
Previous experiments indicated that maternal behavior can epigenetically program 
gene expression (Weaver et al., 2004; Murgatroyd et al., 2009). In the present study 
using an inbred mouse strain, all the mice were housed in the same environment with 
food and water ad libitum; thus, maternal separation was the only environmental 
variable imposed. The results obtained show that ELS leads to hypomethylation of a 
key regulatory region of the pituitary Pomc gene. These epigenetic events are 
accompanied by persistent upregulation of Pomc mRNA expression, and 
consequently, sustained hyperactivation of the HPA axis; the ELS-induced endocrine 
phenotype lasted for at least 1 year. In addition, previous experiments from this 
laboratory (Murgatroyd et al., 2009) on the same cohort of mice found that ELS mice 
displayed increased immobility in the forced swim test, which is an index of 
depression-like behavior in rodents, consistent with the well-established links between 
hypersecretion of adrenocorticoids and mood disturbances in humans. 
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Growing evidence suggests that epigenetic mechanisms, such as DNA 
methylation, affect gene expression in an age-dependent manner. For example, the 
amount of total 5-methylated cytosine was decreased in DNA extracted from 
uncultured peripheral blood human lymphocyte compared between young donors and 
old subjects (Singhal et al., 1987; Drinkwater et al., 1989), and a gradual global loss 
of cytosine DNA methylation was observed in various mouse, rat and human tissues 
(Wilson et al., 1987; Fuke et al., 2004). These observations indicate the possible 
importance of DNA methylation in the ageing process. Global hypomethylation has 
been proposed to affect genetic stability and might be a mechanism responsible for 
cellular senescence (Suzuki et al., 2002).  
Besides global DNA hypomethylation, some specific genes display 
hypermethylation during ageing, probably resulting  the the inactivation of key 
regulatory genes in cancer (Ottaviano et al., 1994; Li et al., 2005; Esteller, 2008). In 
prostate cancer, hypermethylation of the pi-class glutathione S-transferase gene 
(GSTP1) promoter was reported as a very common genomic alteration. As a 
consequence, GSTP1 expression is lost even at the earli st stages of tumorigenesis 
(Lee et al., 1994).  
In this work, DNA methylation drifts during ageing were found at the Pomc gene 
locus. In male control mice, analysis of overall DNA methylation at the distal 
promoter revealed a steady age-related decrease of DNA methylation: from 60% at 6 
weeks to 30% at 1 year as shown in Figure 16. ELS mice also displayed age-
associated DNA hypomethylation, but the effects occurred much earlier than in 
controls. In contrast, DNA methylation levels in females changed less during the 
ageing process, both in the control and ELS groups. In fact, a functional correlation 
between age-associated DNA hypomethylation and increased Pomc transcription in 
the pituitary was observed. These data agree with previous reports that Pomc mRNA 
levels increase with age (Nelson et al., 1988).  
In addition to the observed associations of DNA methylation levels with age, 
there is evidence that DNA methylation levels are also influenced by gender. Several 
studies found higher global DNA methylation levels in males (Fuke et al., 2004; El-
Maarri et al., 2007). Gender differences in DNA methylation can also occur in a gene-
specific manner. For example, gender-specific DNA methylation differences have 
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been intensively investigated with respect to the ERα promoter and a recent report 
suggested that maternal behavior in rodents might regulate DNA methylation status in 
ERα promoter and therefore be responsible for long-lasting effects on gender-specific 
ERα gene expression (Champagne et al., 2006; Kurian et al., 2010). Specifically, 
Champagne and coworkers indicated that variations in maternal care during the early 
postnatal period affect ERα expression in the medial preoptic area (MPOA) by 
altering ERα promoter methylation and that ERα expression is higher in the offspring 
of high LG-ABN dams (Champagne et al., 2006). Correspondingly, the levels of 
cytosine methylation across the ERα promoter were decreased in the adult female 
offspring of high LG mothers, compared with low LG mothers. In another 
experiment, Kurian and colleagues showed that the natural variation in maternal care 
might be responsible for the gender-difference in behavior and neuronal morphology 
in adulthood (Kurian et al., 2010). These authors fund that sex differences in DNA 
methylation of the ERα promoter within the developing rat preoptic area (POA), with 
males exhibiting more DNA methylation within ERα promoter than females. They 
suggested that maternal behavior plays a role in this gender-specific pattern of DNA 
methylation. Since the rodent mother tends to groom the anogenital region of her male 
offspring, it was proposed that grooming behavior may lead to increased estradiol 
secretion, thereby down-regulating ERα expression by increasing methylation at the 
ERα promoter. Together, these results suggest that maternal behavior in early life may 
leave stable epigenetic marks in the genome that organizes long-lasting sex 
differences in the brain.  
Gender-specific DNA methylation differences were found at the Pomc gene 
locus in the pituitary in the present research. Males exhibited more DNA methylation 
within the Pomc distal promoter than females as revealed by bisulfite mapping of the 
entire promoter region and part of coding region (Figure 16). Notably, gender-specific 
differences were only found in the distal promoter region known to be important for 
Pomc gene expression in transfection experiments (Figure 18). Gender differences in 
DNA methylation were negatively correlated with Pomc gene expression in the 
pituitary, with higher levels of Pomc mRNA in female mice compared to male mice. 
Clinical reports indicate that men and women have different susceptibilities to a 
number of diseases. Concerning psychiatric disorders, women develop anxiety, 
depression, phobia, or panic disorders more often tha men, whereas men more often 
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display antisocial behavior and substance abuse (Bebbington, 1996; Weich et al., 
2001). From the present results, it would appear tht increased expression of Pomc 
mRNA in female mice, resulting from hypomethylation in Pomc distal promoter, 
might contribute to differential susceptibility to psychiatric disorders between the 
genders.   
4.3 Site-directed in vitro DNA methylation assay 
Here, bisulfite sequencing revealed that DNA methylation decreased at the Pomc 
distal promoter after ELS. To prove a potential causal relationship between DNA 
methylation on Pomc expression, site-directed DNA methylation assays were 
performed. To this end, a CpG-free luciferase report r (pCpGL-basic) was used. Since 
traditional luciferase vectors contain a number of CpG residues in the backbone that 
might repress a CpG-free promoter when the backbone DNA is methylated (Klug and 
Rehli, 2006), the novel pCpGL vector was designed so as to be free of CpGs in the 
entire sequence, and the reporter was only repressed in the presence of functionally 
important methylated CpG residues in the promoter fragment inserted. Results 
showed that if CpG 6−8 is methylated, Pomc luciferase activity is decreased by 40% 
(Figure 18). In another transfection experiment, deletion of this region (CpG 6−8) 
diminished reporter activity by 60%. All these result  thus provide support for the 
functional importance of this region in the regulation of Pomc gene expression. 
4.4 MeCP2 represses pituitary Pomc expression 
DNA methylation is interpreted by a family of methyl-CpG-binding domain (MeCP) 
proteins which can recruit additional proteins (e.g. histone deacetylase (HDAC) and 
other chromatin remodeling complexes) to induce gene silencing. It was hypothesized 
that methylated DNA in the distal promoter region will recruit specific methyl-CpG-
binding domain proteins to silence Pomc gene expression. To examine this, a series of 
MBD family proteins were co-transfected with methylated Pomc reporter constructs 
into the AtT20 cell line, derived from pituitary corticotropes. Our results showed that, 
compared with the other MBD family members, MeCP2 induced strong repression of 
Pomc expression. RT-PCR and western blot revealed that MeCP2 is strongly 
expressed in both, the pituitary in vivo and in AtT20 cells at the mRNA and protein 
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levels. These results with MeCP2 are the first to describe this protein’s function as a 
repressor in the pituitary. Previous research on MeCP2 was predominantly focused on 
the brain, and it was not until recently that MeCP2 was reported to play a role in 
peripheral tissues such as cardiac and skeletal muscle (Alvarez-Saavedra et al., 2010). 
Since MeCP2 is widely expressed in a number of tissue , all of these new 
observations suggest roles of MeCP2 in non-neural tissues. 
For high affinity DNA binding of MeCP2, two criteria must be met. The first one 
is the presence of methylated CpG dinucleotides; the second one is the presence of 
[AT≥4] runs close to a methylated CpG. Searching for potential binding sites in the 
Pomc DNA sequence revealed that both criteria were fulfilled in the distal promoter 
region; the 5’ UTR region has AT runs but lacks CpG dinucleotides, whereas the 
coding region has CpGs but no AT runs. To test MeCP2 binding to Pomc in vitro, 
electrophoretic mobility shift assays (EMSAs) were p rformed, using recombinant 
MeCP2 and oligonucleotides that located in the distal promoter and core promoter 
region. Two pairs of oligonucleotides that covered the distal promoter region were 
designed, along with another oligonucleotide that targeted the middle region of the 
promoter to serve as a control. The results showed that MeCP2 preferentially binds to 
the methylated oligonucleotides in the distal promoter region of Pomc; in contrast, the 
control oligonucleotide did not bind, irrespective of whether it was methylated or not. 
Binding specificity was also tested by adding excess unlabelled oligonucleotides or by 
adding MeCP2 antibody. When unlabelled oligonucleotides or MeCP2 antibody was 
added to the reaction, MeCP2 binding was abolished. Further, a series of mutation 
studies showed the importance of methylated CpG and AT runs for MeCP2 binding. 
For example, when the wild type oligonucleotide was methylated at CpG6, about 5% 
of oligonucleotide was bound, whereas no binding was observed with unmethylated 
oligonucleotide. When one of the AT runs was mutated, binding was significantly 
affected, and an effect was seen when CpG7+8 were mthylated. Taken together, 
these results indicate that the Pomc distal promoter (CpG6−8) contains context-
specific, high-affinity MeCP2 DNA-binding sites that re important for the regulation 
of Pomc gene expression. 
EMSA experiments indicated that MeCP2 binds to the Pomc distal promoter. In 
order to confirm the repressive function of MeCP2 at this locus, sequential ChIP 
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(seqChIP) on mouse pituitary was performed, using atibodies against either active 
(H3Ac) or repressive (H3K9me2) histone marks  in the first round of ChIP. A second 
round of ChIP with anti-MeCP2 antibody showed that MeCP2 is preferentially 
associated with H3K9me2 at the Pomc promoter region. To further indentify the 
corepressor recuited by MeCP2 to the Pomc promoter, another seq-ChIP was 
performed on mouse pituitaries. MeCP2 antibody was used for the first round ChIP. 
In the second round, antibodies against either HDACs (Hdac1, Hdac2, Hdac4) or 
DNMTs (Dnmt1, Dnmt3a, Dnmt3b) were used. Sequential ChIP assays demonstrated 
that MeCP2 is associated with Hdac2 as well as Dnmt1 at the Pomc promoter. 
Previous literature indicated that HDAC2 and Brg1, the ATPase subunit of Swi/Snf 
complex, are involved in the GR-directed trans-repression  of Pomc in the rat pituitary 
(Bilodeau et al., 2006). In vivo, Brg1 is required to stabilize the interaction between 
GR and Nur77 (also called NGFI-B) as well as between HDAC2 and Nur77. Nur77 
residues in the NurRE site in the Pomc distal promoter region, where MeCP2 binds 
with high affinity. It should be noted that a number of reports have indicated an 
interaction between MeCP2 and HDACs (Nan et al., 1998; Suzuki et al., 2003); thus, 
it is possible that MeCP2 is also involved in GR-mediated trans-repression in the 
Pomc promoter and that Hdac2 mediates this event. 
4.5 Experience-dependent phosphorylation of MeCP2 
In the brain, neuronal activity can dynamically regulate gene transcription through 
phosphorylation of MeCP2 in response to diverse extracellular stimuli. For example, 
previous studies showed that phosphorylation of MeCP2 at serine 421 in cultured rat 
neurons precedes the release of MeCP2 from the Bdnfpromoter, resulting in an 
increase in BDNF expression (Chen et al., 2003). It was shown that MeCP2 
phosphorylation is controlled by neuron activity-dependent calcium influx and a 
CaMKII mediated mechanism. In spite of the ubiquitos expression of MeCP2 
(Shahbazian et al., 2002b), its functions have so far nly been studied in the context of 
the brain. Previous research pointed out that altered MeCP2 expression in cardiac and 
skeletal tissues has detrimental effects during normal development (Alvarez-Saavedra 
et al., 2010). Phospho-MeCP2(438) (homolous to rat phospho-421 MeCP2) antibody 
recognizes MeCP2 in the mouse heart isolated as early as E12.5 days, whereas 
MeCP2 cannot be detected in heart from adult mice or Mecp2-/Y null mice. This 
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finding suggests that MeCP2 phosphorylation is not brain specific, and supports a 
functional role for MeCP2 in tissues besides brain. In the present study, it was found 
that MeCP2 is ubiquitously expressed in pituitary cells, with high expression in 
corticotrope cells. Moreover, MeCP2 was found to be phosphorylated at serine 438 in 
cultured mouse primary pituitary cells upon membrane depolarization by KCl (Figure 
26B); the latter was associated with an increase in the expression of Pomc mRNA 
(Figure 29B). Notably, membrane depolarization induced phosphorylation of MeCP2 
was not confined to corticotrope cells, as evidenced by the presence of phospho-438 
MeCP2 in ACTH- positive and -negative cells (Figure 26B). The idea that MeCP2 
phosphorylation is required for activity-dependent ac ivation of the Pomc gene was 
supported by overexpression of a non-phosphorylatable mutant form of MeCP2 
(S438A), which inhibits Pomc induction in response to active CaMKII; it was also 
shown that the latter inhibition is dependent on DNA binding (Figure 29). Thus, 
MeCP2 phosphorylation at serine 438 results in a decreased binding of MeCP2 to 
Pomc promoter. 
MeCP2 phosphorylation occurs in response to physiolog cal stimuli such as light 
exposure during the subjective night or cocaine administration (Mao et al., ; Zhou et 
al., 2006). It was therefore asked whether MeCP2 phos orylation could be triggered 
in a psychological context in the pituitary. As we know, MeCP2 phosphorylation is 
driven by calcium influx and CaMKII activity. Previous research showed that AVP 
activates Pomc expression through binding to the V1b receptor at the corticotrope cell 
membrane; this event initiated calcium influx. Results shown in Figure 30 
demonstrate that increased calcium levels stimulate CaMKII enzymatic activity, 
resulting in phosphorylation of MeCP2 in pituitary cells upon AVP stimulation. 
Interestingly, MeCP2 phosphorylation occurs predominantly in corticotrope cells 
expressing the AVP V1b receptor (Figure 30B). Supporting this, it was found that 
AVP-induced MeCP2 phosphorylation can be  blocked by pre-treatment with the 
AVP V1b receptor antagonist---SSRI 149415 (Figure 30B). Specificity of the effect 
was further demonstrated in an experiment in cortictrope AtT20 cells which had 
been stably transfected with an AVP V1b receptor since they lack expression of this 
receptor (Figure 31).  
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Previous research in our laboratory has shown that ELS produces long-lasting 
elevations of the levels of AVP mRNA and peptide in the hypothalamus. The present 
results show that MeCP2 phosphorylation status can be dynamically regulated by 
AVP in pituitary cells (Figure 30). Taken together, these findings suggest that ELS 
can trigger the dynamic modification of MeCP2 via AVP stimulation. Our results 
demonstrate that early life adversity can lead to epigenetic marking of the genome by 
reducing MeCP2 occupancy at the Pomc promoter in ELS mice (Figure 34, 35).  
During mammalian cell division, DNA methylation patterns can be faithfully 
copied to the newly synthesized daughter strand. This process depends on the 
maintenance of DNA methyltransferase activity. Pituitary cells proliferate postnatally, 
especially during the first postnatal days. During this process, a co-repressor complex, 
comprising MeCP2, Hdac2 and Dnmt1, appears to contribute to maintaining DNA 
methylation in dividing pituitary cells. Maternal separation induces AVP expression 
in the hypothalamic PVN which, in turn, leads to higher levels of MeCP2 
phosphorylation. As a consequence, MeCP2 dissociates from the Pomc promoter, 
resulting in a loss of binding of co-repressors such as Hdac2 and Dnmt1. Dnmt1 is a 
methyltransferase which is responsible for maintenance of DNA methylation patterns 
during cell replication. Due to the loss of Dnmt1 binding at the Pomc promoter, when 
pituitary cells experienced mitosis, the DNA methylation pattern cannot be faithfully 
maintained, leading to passive DNA demethylation. O the other hand, the DNA 
methylation pattern is well preserved during pituitary cell mitosis in control animals 
due to the relatively higher levels of MeCP2 as well as Dnmt1 at the Pomc promoter. 
4.6 Model  
Early life stress produced long-lasting alterations f the HPA axis characterized by 
elevated corticosterone level, increased Pomc mRNA levels in the pituitary as well as 
hypersecretion of ACTH into the blood. Epigenetic mechanisms, especially DNA 
methylation, appear to be responsible for controlling Pomc gene expression by 
recruiting MeCP2 to silence the gene. We showed that ELS mice displayed reduced 
occupancy of MeCP2 at the Pomc promoter both in early postnatal days (PND10) and 
in adulthood (6 weeks). As shown previously, MeCP2 preferentially binds to 
methylated CpG residues. This decreased occupancy of MeCP2 in ELS mice at the 
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Pomc locus could result from hypo-methylation of multiple CpG residues (CpG 6−8) 
at the Pomc distal promoter region. As a consequence, reduced CpG methylation level 
weakened the MeCP2 binding affinity to its recognitio  sites. However, there seems 
to be a distinct MeCP2 binding pattern in early postnatal days. We observered a 
reduced MeCP2 occupancy in Pomc promoter region, which correlated with higher 
Pomc mRNA level in ELS mice, while this differential binding could not be explained 
by methylation alterations since there was no difference in DNA methylation between 
ELS mice and controls. This paradoxical finding implied that MeCP2 binding could 
be regulated by other mechanisms besides DNA methylation, such as phosphorylation.  
Immunostaining of primary pituitary cells showed that MeCP2 is phosphorylated 
at serine 438 by membrane depolarization after KCl treatment. Interestingly, 
treatment of primary pituitary cells with hypothalamic peptide AVP could also induce 
MeCP2 phosphorylation at serine 438 by activation of CaMKII activity. MeCP2 
serves as a platform, to which Hdac2 and Dnmt1 can bind, to repress Pomc gene 
activity. Pituitary cells proliferate postnatally, especially during the early postnal days. 
During this process, this co-repressor complex (MeCP2, Hdac2 and Dnmt1) could 
help the pituitary cells to maintain DNA methylation during pituitary cell mitosis. 
Maternal separation induced higher levels of AVP expr ssion in the PVN of the 
hypothalamus which in turn leads to higher level of MeCP2 phosphorylation. As a 
consequence, MeCP2 becomes phosphorylated and dissociated from the Pomc 
promoter resulting in loss binding of co-repressor complex such as Hdac2 and Dnmt1. 
Dnmt1 is a methyltransferase which is responsible for maintenance of DNA 
methylation pattern during cell replication. Due to the loss of Dnmt1 binding at the 
Pomc promoter during mitosis, DNA methylation pattern could not be faithfully 
maintained, probably promoting passive DNA demethylation. On the contrary, in the 
control animals DNA methylation pattern is well preserved during pituitary cell 
mitosis since relatively higher level of MeCP2 as well as Dnmt1 are present at the 
Pomc promoter. 
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Figure 46. Model of how early life stress (ELS) leads to epigenetic upregulation of Pomc gene 
expression. Early life stress produces long-lasting increases in the activity of the HPA axis, 
characterized by increased pituitary Pomc mRNA expression, ACTH secretion and elevated levels 
of corticosterone. Epigenetic mechanisms, especially DNA methylation, appear to be responsible 
for controlling Pomc gene expression by recruiting MeCP2 to silence the gene under baseline 
(control) conditions. ELS mice display reduced occupancy of MeCP2 at the Pomc promoter, 
resulting from hypomethylation of multiple CpG residues (CpG 6−8) in the distal promoter region 
of Pomc. In addition, MeCP2 binding affinity is also regulated by phosphorylation at serine 438. 
When MeCP2 is phosphorylated at serine 438, the configuration of MeCP2 protein might change 
and MeCP2 dissociates from the Pomc promoter, leading to loss of binding of co-repressor 
complexes such as Hdac2 and Dnmt1. Pituitary cells proliferate postnatally. During this mitosis, 
co-repressor complexes (MeCP2, Hdac2 and Dnmt1) mayfacilitate maintenance of DNA 
methylation. The maternal separation (ELS) paradigm induces higher levels of AVP expression in 
the hypothalamic PVN (Murgatroyd et al., 2009) which, in turn, leads to higher levels of MeCP2 
phosphorylation. As a consequence, MeCP2 proteins, together with co-repressor complexes, 
dissociate from the Pomc promoter, resulting in increased Pomc expression. Dnmt1 is a 
methyltransferase involved in maintenance of DNA methylation patterns during cell replication. It 
is hypothesized that loss of Dnmt1 binding at the Pomc promoter during mitosis, does not allow 
faithful duplication of the parental DNA methylation pattern and results in passive DNA 
demethylation. On the contrary, the DNA methylation pattern is well preserved during pituitary 
cell mitosis in control animals because of the relatively higher levels of MeCP2 and Dnmt1 at the 
Pomc promoter. 
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5 Summary 
Early-life stress (ELS) can lead to enduring changes in the structure and function of 
neural circuits and endocrine pathways, resulting in altered vulnerability thresholds 
for stress-related disorders such as depression and anxiety.    
The question addressed in this work was whether epigenetic mechanisms contribute to 
the long-term programming of altered hypothalamus-pituitary-adrenal axis activity in 
ELS (maternal separated on postnatal days 1-10) mice.  
Adrenocorticotropic hormone (ACTH), a key pituitary mediator of the adrenocortical 
response to stress, is encoded by the proopiomelanocortin (Pomc) gene. Corticotropin 
releasing hormone (CRH) and arginine vasopressin (AVP) are the main upstream  
neural regulators of Pomc gene expression and the post-translational processing of its 
peptidergic products, whereas glucocorticoids, secret d by the adrenals in response to 
stress, exert negative feedback actions on Pomc synthesis and ACTH secretion. It was 
shown that Pomc mRNA level is persistently increased in ELS mice and leads to 
sustained hypersecretion of glucocorticoids. Interestingly, ELS causes a reduction in 
DNA methylation at a critical regulatory region of the Pomc gene; this occurs with 
some delay after onset of the stress and persists for up to 1 year. A series of 
experiments (including reporter-, EMSA-, IHC- and ChIP-assays) supported the 
concept that the adverse early-life event induces changes in Pomc gene methylation 
and results in persistently upregulated expression of the Pomc gene. Interestingly, 
stress-induced changes in DNA-methylation were found to be more pronounced in 
males than in females, raising the possibility thatepigenetic encoding occurs in a sex-
specific manner; this may help to explain sex differences in susceptibility to stress-
related disorders.  
Collectively, the results of this study indicate that epigenetic mechanisms can serve to 
translate environmental cues into stable changes (“cellular memory”) in gene 
expression in post-mitotic tissues, without the need for alterations in the genetic code. 
Keywords:  early life stress (ELS), proopiomelanocortin (Pomc), epigenetics, DNA 
methylation, MeCP2                         
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7 Abbreviations 
 
7.1 Standard 
 
35S Sulphor-isotope 35 5’UTR 5' Untranslated region 
5hmC 5’ Hydroxymethyl cytosine 5mC 5’ Methyl cytosine 
aa Amino acids A Adenine 
C Cytosine cDNA Complementary DNA 
cm,mm Centimeter, Millimeter cpm Counts per Minute 
DNA Deoxyribonucleic acid EMSA Electrophoretic mobility shift assay 
G Guanine g Gram 
h, min, sec Hour, Minute, Second kb Kilobase 
kDa Kilodalton l Litre 
µ Micro m Milli 
M Molar mRNA Messenger RNA 
n Nano OD Optical density 
PCR Polymerase chain reaction RNA Ribonucleic acid 
rRNA Ribosomal RNA RT Room temperature 
RT-PCR Reverse transcription PCR T Thymine 
Tm Melting temperature U Uracil 
Vol Volume W Watt 
 
 
7.2 Buffers and substances 
 
Ac Acetate ATP Adenosine-5'-triphosphate 
BSA Bovine serum albumin ddH2O di-distilled water 
DEPC Diethylpyrocarbonate DMEM Dulbecco's Modified Eagle Medium 
DMSO Dimethyl sulfoxide dNTP Deoxyribonucleotide 
DTT Dithiothreitol EDTA Ethylendiamintetraacetate 
FCS Fetal calf serum GST Glutathione-S-transferase 
HEPES 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid 
IPTG Isopropyl β-D-1-thiogalactopyranoside 
PAGE Polyacrylamid gel electrophoresis PBS Phosphate buffered saline 
SDS Sodium dodecyl sulfate TBS Tris-buffered saline 
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TE Tris-EDTA buffer TEMED Tetramethylethylenediamine 
Tris Tris-(hydroxymethyl)- 
aminomethane 
X-Gal Bromo-chloro-indolyl- 
galactopyranoside 
 
 
7.3 Non-standard 
 
ACTH Adrenocorticotropic hormone AP-1 Activator protein 1 
AVP Arginine vasopressin AVP v1bR AVP v1b receptor  
CaMKII Calcium/calmodulin kinase II cAMP Cyclic adenosine monophosphate  
CGI CpG island ChIP Chromatin immunoprecipitation 
CpG Cytosine-phosphate- guanine CRH Corticotropin-releasing hormone 
DEX Dexamethasone Dnmt DNA-methyl-transferase 
E.coli Escherichia coli ELS Early-life stress 
FLAG DYKDDDDK GAPDH Glyceraldehyde-3-phosphate 
dehydrogenase 
GR Glucocorticoid receptor H3Ac Histone 3 acetylation 
H3K9me2 Histone 3 lysine 9 dimethylation HAT Histone acetyltransferase 
HDAC Histone deacetylase His Histone 
HPA Hypothalamic-pituitary-adrenal HPRT Hypoxanthine guanine phosphoribosyl 
transferase 
MeCP2 Methyl CpG binding protein 2 NGFI-B Nerve growth factor-induced protein B 
Nur77 Orphan receptor family nuclear 
protein 
RNA Pol II RNA polymerase II 
POMC Proopiomelanocortin PVN Paraventricular nucleus 
SP1 Transcription factor SP1 SSRI Selective serotonin re-uptake inhibitors 
 
ACKNOWLEDGMENTS 
 
113 
 
8 Acknowledgments 
 
This work was performed at the Max Planck Institute of Psychiatry, in the laboratory of molecular 
endocrinology under the supervision of Dr. Dietmar Spengler.  
 
First of all, I would also like to thank institute’s head, Prof. Dr. Dr. Dr. h. c. Florian Holsboer fo
giving me the opportunity to work in this institute.  
 
I would like to thank Prof. Dr. Rainer Landgraf for accepting me as his registered PhD student in 
Ludwig-Maximilians-Universität München. His help, support and encouragement have been 
indispensable for me to pursue the doctor’s degree. 
 
I would like to express my gratitude to Dr. Spenlger for offering me the chance to join his group and 
work on the scientific field of epigenetics. Thanks to Dr. Spengler for his supervision, his in-depth 
knowledge and valuable suggestions. 
 
I am grateful to Dr. Osborne Almeida for his continuous help, support, patience, understanding, 
friendship, encouragement and concern during my sta.  He has always been available to discuss all 
kinds of questions during my work, and has generously shared his knowledge and support. 
 
I would like to thank Professor Dr. Günter K. Stalla and Dr. Ulrich Renner for their substantial support 
and encouragement to help me finish my PhD work and for giving me more perspective for my career. 
I would like to thank Guillaume Daniel, Yannick Menger and Dr. Alexandre Patchev for their 
enthusiastic help with the experiments and also for their substantial support during my PhD life.  
I would like to thank all my colleagues in the lab for the friendly, cooperative environment they have 
provided me and also for their selfless and enthusiastic help. I would like to give many thanks to Anke 
Hoffmann, Dr. Christopher Murgatroyd, Dr. Yvonne Bockmühl, Dieter Fischer, Marc Bettscheider, 
Udo Schmidt, Dr. Thomas Arztberger, Dr. Bing Shan, Johanna Stalla, Bärbel Wölfel, Dr. Marily 
Theodoropoulou and Jose Luis Monteserin Garcia. I hve spent a lot of joyful time with all of them and 
this wonderful memory will never fade away.  
 
To all my friends, who contributed in this and that way to my working and private success, I think of 
you and thank you a lot. 
 
Last but not least, I want to deliver my deepest gra itude to my beloved parents and my sister in China, 
my girlfriend Yanan Yin in Munich. They have showed normous love and support to me, which have 
been the greatest inspiration to my work. 
CURRICULUM VITAE 
 
114 
 
9 Curriculum Vitae 
 
Yonghe Wu 
 
Kraepelinstrasse 12 
80804 München 
+49-17652706857 
yonghe@mpipsykl.mpg.de 
 
Born on 5th August 1977 in Heilongjiang, P.R.China 
 
EDUCATION 
Aug 2005  –  Max Planck Institute of Psychiatry, Munich, Germany 
AG Molecular Neuroendocrinology 
Doctoral thesis submitted “Epigenetic programming of POMC 
by early life stress” 
Sep 2002 – Jun 2005 Chinese Academy of Medical Sciences & Peking Union 
Medical College, Beijing, China 
Dept. Human Genetics; Master of Science  
Research: Screening human breast cancer type1 susceptibility 
gene (BRCA1) mutations by DHPLC in Chinese population 
Sep 1997 – Jun 2001 Central University for Nationalities, Beijing, China 
Dept. Chemistry Engineering, Bachelor of Technology 
Research: Extracting ginkgo flavone and ginkolide from ginkgo 
folium 
 
 
WORKING EXPERIENCE 
Mar 2002 – Jun 2002      Beijing Genomics Institute, Chinese Academy of Science, 
Beijing, China 
                                        Staff member in the institute director office 
